

## Author Index to Volumes 37-43

- Abe S, 38:61; 40:47  
 Abe T, 37:133  
 Adhvaryu SG, 37:291  
 Agbor P, 39:203  
 Ajmar F, 42:253; 43:51;  
     43:57; 43:195  
 Åkerman M, 41:93  
 Akiyama Y, 40:73  
 Aledo R, 40:95  
 Alimenta G, 40:149;  
     40:163; 40:171;  
     40:187; 40:203  
 Allen GJ, 43:67  
 Aloesio R, 37:23  
 Amakawa R, 40:73  
 Amess JA, 39:295  
 Anderson AE, 43:67  
 Anderson DE, 38:241  
 Andren-Sandberg A,  
     37:209  
 Angrilli F, 41:49  
 Antonini P, 41:139  
 Arden KC, 37:55  
 Arheden K, 37:139;  
     39:195; 42:143  
 Arnemann J, 37:141  
 Arsenis P, 40:83  
 Arthur DC, 40:163;  
     40:187; 40:203  
 Artusi T, 38:101; 41:203  
 Asou N, 43:139  
 Aster JC, 39:185  
 Atkin NB, 37:229; 40:3  
 Attas L, 39:25  
 Audebert AA, 42:55  
 Auersperg N, 38:53  
 Aurias A, 37:65; 40:95;  
     42:43  
 Avanzi G, 39:77  
 Avril MF, 40:95  
  
 Babin P, 37:279  
 Babinska M, 37:153;  
     38:215  
 Babu VR, 38:127  
  
 Bacigalupo A, 42:253  
 Badzioch M, 38:241  
 Baer MR, 39:55; 39:119  
 Baker MC, 37:229  
 Balboni M, 37:29  
 Bale AE, 42:273  
 Bale SJ, 42:273  
 Balough E, 43:179  
 Baran W, 37:153  
 Barbata G, 37:127  
 Bard R, 42:35  
 Bardi G, 40:83  
 Barrett JC, 38:271  
 Barrios L, 41:61  
 Barsoum-Homsy M,  
     43:73  
 Bartnitzke S, 39:65  
 Battaglio S, 39:77  
 Battista R, 37:263  
 Bauer HCF, 42:27  
 Bauters F, 37:9; 39:45  
 Becher R, 37:95  
 Beckwith JB, 41:79  
 Behm FG, 40:13  
 Bello MJ, 38:133; 41:175  
 Bénard J, 39:35  
 Ben-Bassat I, 38:131  
 Benoit Y, 40:29  
 Berger CS, 39:281; 41:99;  
     43:15  
 Berger J, 43:219  
 Berger R, 38:1; 40:187;  
     40:203; 41:139  
 Berkowicz M, 38:131  
 Bernstein R, 39:81  
 Besa EC, 42:1  
 Beverstock GC, 40:121  
 Bhargava M, 42:35  
 Biegel JA, 38:89  
 Bielfeld V, 43:219  
 Bigner SH, 40:111  
 Biörklund A, 37:235;  
     39:29; 39:69; 39:227  
 Birch JM, 42:221  
 Bitter MA, 37:1  
  
 Bjermer I, 38:297  
 Bloomfield CD, 40:163;  
     40:171; 40:203  
 Boccadoro M, 39:77  
 Boghosian L, 43:39  
 Böhm A, 41:129  
 Boice CR, 43:1  
 Boldog F, 42:295  
 Bolund L, 37:179  
 Boogaerts M, 43:227  
 Borowska-Lehman J,  
     38:215  
 Bosly A, 42:209; 43:227  
 Bouts MJ, 42:115  
 Brecher ML, 39:125  
 Breitbart EW, 41:129;  
     43:219  
 Briand P, 39:103  
 Briault S, 37:279  
 Bridge JA, 38:83  
 Brizard A, 37:279  
 Brizard CP, 42:67  
 Brodeur GM, 41:153  
 Brok-Simoni F, 38:131  
 Brosjö O, 42:27  
 Brothman AR, 37:241  
 Browett PJ, 37:169  
 Brusa P, 37:285  
 Budman DR, 39:25  
 Bull M, 38:49  
 Bullerdiek J, 39:65  
 Burns ER, 42:35  
 Burns J, 43:67  
 Burns TL, 39:157  
 Bussolati G, 37:79  
 Buys CHCM, 38:1  
  
 Caballín MR, 41:61  
 Cagle PT, 39:219  
 Caillou B, 41:139  
 Calabrese G, 39:139;  
     41:49  
 Callen DF, 38:255  
 Canaani D, 40:65  
 Caporossi D, 40:135

- Carbone P, 37:127  
 Casartelli C, 40:33  
 Casorzo L, 37:79  
 Casper J, 37:141  
 Cassiman JJ, 41:19  
 Castedo SMMJ, 41:105  
 Castoldi G, 37:29  
 Catovsky D, 40:149  
 Cavalli IJ, 41:71  
 Celso B, 42:191  
 Cepulić M, 42:147  
 Cerney JC, 38:127  
 Chaganti RSK, 37:85;  
 43:67  
 Chauvenet AR, 37:221  
 Chen MS, 42:203  
 Chen Y, 39:89  
 Chidambaram A, 38:241  
 Chien S, 39:89  
 Christensen IB, 39:245  
 Christensen IJ, 37:179  
 Chuang SM, 39:89;  
 42:203  
 Chuang SM, 42:203  
 Ciancarelli M, 41:49  
 Cintonino M, 43:95  
 Cirocco L, 38:255  
 Clarke JM, 38:121  
 Clarkson B, 37:85  
 Cooke HMG, 37:169;  
 42:263  
 Corradini P, 39:77  
 Couderc P, 43:243  
 Couzigou P, 37:285  
 Crampton J, 43:203  
 Crossen PE, 43:143  
 Cuneo A, 37:29; 42:209  
 Cunningham I, 43:67  
 Czepulkowski BH, 39:295  
  
 Dahlenfors R, 37:215  
 Dal Cin P, 37:157;  
 37:281; 39:21; 40:29;  
 42:209; 42:243; 43:39  
 Dam A, 41:105  
 Damasio E, 43:51  
 Dao D, 42:287  
 Da Silva J, 39:35  
 Dave BJ, 37:291  
 Davis EM, 37:1  
 De Braekeleer M, 37:163  
 Debray J, 42:55  
 de Campos JM, 41:175  
 Decker HJH, 39:289;  
 41:99  
 Defferrari R, 42:253;  
 43:51; 43:57; 43:195  
  
 de Gramont A, 42:55  
 Dejana AM, 43:57  
 de Jong B, 38:25; 38:33;  
 40:129; 41:105  
 de Koning J, 41:105  
 de la Chapelle A, 40:149;  
 40:163; 40:171;  
 40:187; 40:203;  
 41:211  
 Delahaye M, 42:115  
 de Leij LFMH, 38:1  
 Delhanty JDA, 42:263  
 D'Emilio A, 37:263  
 Deminatti M, 37:9; 39:45;  
 42:307  
 den Nijs van Weert JL,  
 40:121  
 Dennis TR, 37:201  
 De Potter KR, 39:21;  
 40:29  
 Dermitzaki K, 40:83  
 De Telder V, 40:29  
 Dewald GW, 39:167;  
 39:253; 40:149;  
 40:187; 40:203;  
 42:173  
 Dhaliwal MK, 41:145  
 Di Bartolomeo P, 41:49  
 Dijkhuizen T, 38:33  
 Diklić V, 42:135  
 Di Lernia R, 38:223  
 Dini E, 37:263  
 DiPaolo JA, 42:157  
 Divelbiss JE, 39:157;  
 42:227  
 Di Virgilio C, 39:139  
 Doi S, 40:73  
 Dokter J, 38:25; 38:33  
 Doneda L, 38:223  
 Dragone P, 37:263  
 Drochmans A, 42:243  
 Dubé ID, 38:261; 40:105  
 Dumont J, 42:43  
 Dutrillaux B, 37:65;  
 38:205; 40:95; 42:43  
  
 Edström S, 39:153  
 Egozcue J, 41:61  
 Elder FFB, 39:219  
 Elfving P, 39:191  
 Emanuel BS, 38:89  
 Emilia G, 38:101; 41:203  
 Erdtmann B, 41:71  
 Erlandsson R, 42:295  
 Estienne MH, 37:9; 39:45;  
 42:307  
 Euler H, 41:87  
  
 Fagioli F, 37:29  
 Fan SX, 41:99  
 Faustinella F, 39:137  
 Feller A, 41:87  
 Fenaux P, 37:9; 39:45;  
 42:307  
 Ferrari L, 37:29  
 Ferrari S, 38:101  
 Ferre D, 39:35  
 Ferrell RE, 38:241  
 Fessia L, 37:79  
 Filippa DA, 37:85; 43:109  
 Finze EM, 42:75  
 Fischer A, 38:205  
 Fitzgerald PH, 42:9  
 Fletcher JA, 39:185;  
 41:115  
 Flodérus UM, 42:51  
 Fonatsch C, 37:141  
 Fong C, 41:153  
 Forabosco A, 37:23  
 Fraccaro M, 42:309;  
 43:89; 43:249  
 Franchi PG, 39:139  
 Frassoni F, 42:253;  
 43:195  
 Friedman HS, 40:111  
 Fugazza G, 43:57  
 Fujiwara A, 43:79  
 Fukuda W, 40:73  
 Fukuhara S, 40:73  
 Fundia AF, 41:41  
 Furuya T, 43:131  
 Fuster C, 41:61  
  
 Garber JE, 39:141  
 Garewal HS, 42:281  
 Garre ML, 37:19  
 Garson OM, 40:149;  
 40:171; 40:187;  
 40:203  
 Gaud C, 38:205  
 Gemmill RM, 39:289  
 Geraci L, 41:49  
 Geraedts JPM, 42:87  
 Geurts van Kessel A,  
 40:129  
 Gibbons B, 39:295  
 Giglio MC, 37:127  
 Giovinazzo B, 39:77  
 Goldman AI, 40:171  
 Golomb HM, 40:171;  
 40:203  
 Gonzalez-Canali G, 42:55  
 Gotti G, 43:95  
 Gradl G, 37:141  
 Granata G, 37:127  
 Greaves MF, 40:217

- Greger V, 37:95  
 Grois N, 43:119  
 Guanciali Franchi P, 41:49  
 Guedea F, 41:61  
 Guerra P, 39:137  
 Guerrasio A, 42:191  
 Guilhot F, 37:279  
 Gurll NJ, 42:227
- Haak HL, 40:121  
 Haas OA, 43:119  
 Habibian R, 38:229  
 Hagemeyer A, 40:187; 40:203; 42:67; 42:115  
 Hagger D, 37:293  
 Halbrecht I, 38:43  
 Halligan GE, 41:123  
 Hampton A, 37:85  
 Han T, 39:119  
 Hansen HE, 37:179  
 Harris K, 37:281  
 Harris M, 42:221  
 Hart C, 43:203  
 Hartley AL, 42:221  
 Haupt R, 37:19  
 Havel G, 37:215  
 Havik-Bogaard FCT, 40:121  
 Haworth C, 37:293  
 Hayashi Y, 40:13  
 Hayward NK, 39:233  
 Headley C, 42:227  
 Hecht F, 42:153; 42:313  
 Heim S, 37:61; 37:139; 37:209; 37:235; 39:29; 39:69; 39:191; 39:195; 39:227; 40:137; 41:93; 42:27; 42:51; 42:143; 42:187  
 Hellmann A, 37:153  
 Herrmann ME, 39:65  
 Himmler A, 41:87  
 Hino O, 37:273  
 Hittelman WN, 39:203  
 Holmgren G, 38:297  
 Honjo T, 40:73  
 Hoogsteden HC, 42:115  
 Horii M, 40:73  
 Horiike S, 37:133  
 Hörnsten P, 38:297; 39:147  
 Horsthemke B, 37:95  
 Hou PK, 42:203  
 Howard P, 43:203  
 Huat JJ, 37:9; 39:45
- Inazawa J, 37:133  
 Inoue K, 37:133  
 Igbal MA, 42:35  
 Ishihara T, 38:61  
 Iurlo A, 43:227  
 Ivett J, 42:273
- Jacob MC, 43:243  
 Jalbert P, 43:243  
 James GK, 38:53  
 Jani Sait SN, 37:157; 37:281; 43:39  
 Jaskiewicz J, 38:215  
 Jaubert J, 42:67  
 Jenkins RB, 39:167; 39:253  
 Jhanwar SC, 37:85; 43:67; 43:109  
 Jiang X, 42:287  
 Jin Y, 37:235; 39:29; 39:69  
 Jockin H, 39:125  
 Johansson B, 37:209; 37:235; 39:69; 39:227  
 Johnson B, 38:75  
 Jonsson N, 37:235; 39:69; 39:227  
 Jordan DK, 39:157; 42:227  
 Jouet JP, 37:9
- Kadota RP, 38:9  
 Kallinikou-Maniatis A, 40:83  
 Kalousek DK, 38:53  
 Kalwinsky DK, 40:13  
 Kaneko Y, 40:163; 40:171; 40:203  
 Kanfer E, 37:293  
 Karakousis CP, 37:281; 39:281; 43:39  
 Karmazin N, 41:123  
 Kawaguchi T, 37:273  
 Kawano F, 43:139  
 Kelsey AM, 42:221  
 Kerim S, 42:209  
 Kier P, 43:119  
 Kievits T, 40:121  
 Kimmel DW, 39:253  
 Kimura N, 37:193  
 Kingsley EC, 43:35  
 Kinniburgh AJ, 37:193  
 Kiss A, 43:179  
 Kitagawa T, 37:273  
 Klar D, 38:43  
 Klein EA, 43:67  
 Klein G, 42:295  
 Knuutila S, 41:1
- Koduru PRK, 37:85; 43:109  
 Kojima S, 43:139  
 Kok K, 38:1  
 Konings AWT, 38:25; 38:33  
 Kopacz A, 38:215  
 Kornips F, 42:87  
 Kovacs G, 37:285  
 Kovács I, 43:179  
 Kozman HM, 38:121  
 Krieger O, 43:119  
 Kristoffersson U, 39:191; 41:93  
 Krulik M, 42:55  
 Kusak ME, 41:175
- Ladaga LE, 37:241  
 Lai JL, 37:9; 39:45; 42:307  
 Lambiase S, 43:89; 43:249  
 Langeveld A, 40:129  
 Larizza L, 38:223; 39:137  
 Larripa IB, 41:41  
 Larsen JK, 37:179; 39:245  
 Larson RA, 37:1  
 László A, 39:181  
 Laureys G, 39:21  
 Lawler SD, 40:141; 40:149; 40:163; 40:171; 40:187; 40:203  
 Le Beau MM, 37:1  
 Lecca U, 37:49  
 Lee FY, 39:89; 42:203  
 Leeksa CHW, 40:121  
 Lemieux N, 40:55; 43:73  
 Lemstra W, 38:25; 38:33  
 Leong SPL, 37:281; 39:281  
 Lepelley P, 37:9; 39:45  
 Le Petit JC, 42:67  
 Leroux D, 43:243  
 Leroy J, 39:21; 40:29  
 Lesho LJ, 37:241  
 Letarte M, 42:129  
 Leung TK, 43:73  
 Li P, 42:107  
 Liang JC, 42:287  
 Lichtman SM, 39:25  
 Lieberman PH, 37:85; 43:109  
 Limon J, 37:153; 38:215; 39:191  
 Linares G, 41:139  
 Lipinski KK, 41:115  
 Little MH, 38:121



- Liu C, 39:89; 42:107  
 Liu Y, 42:281  
 Lobeck H, 39:65  
 Löffler H, 41:87  
 Longy M, 37:285  
 Loughran A, 38:75  
 Louwagie A, 42:209;  
 43:227  
 Lu G, 39:233  
 Lundgren R, 39:191  
  
 Maccherini M, 43:95  
 Macera MJ, 38:115  
 Magnani I, 38:223  
 Maher EJ, 39:133  
 Mamuris Z, 37:65; 42:35  
 Mandahl N, 37:61;  
 37:139; 37:209;  
 37:235; 39:29; 39:69;  
 39:191; 39:195;  
 39:227; 40:137;  
 41:93; 42:27; 42:51;  
 42:143; 42:187  
 Mareni C, 42:253; 43:51;  
 43:195  
 Marino TR, 38:241  
 Mark J, 37:215; 39:153;  
 40:111; 41:33  
 Marsden HB, 42:221  
 Martin J, 43:203  
 Martin-DeLeon PA, 40:89  
 Martinowitz U, 38:131  
 Mascarello JT, 38:9  
 Massaad L, 38:205  
 Mattevi MS, 41:71  
 Mauhin C, 37:285  
 Mayne KM, 39:133  
 McDowell H, 43:203  
 McGavran L, 41:79  
 McLachlan JA, 38:271  
 McNay JW, 37:221  
 Mecucci C, 40:149;  
 43:227  
 Medchill MT, 41:99  
 Meloni-Balliet AM,  
 37:269; 43:35  
 Merchant DJ, 37:241  
 Mertens F, 37:209;  
 37:235; 39:69; 39:227  
 Miceli S, 42:253  
 Michaud J, 43:73  
 Michaux JL, 42:209;  
 43:227  
 Mičić M, 42:135  
 Mičić S, 42:135  
 Migliari R, 41:149  
 Mikuni C, 40:47  
 Milašin J, 42:135  
  
 Miles BJ, 38:127  
 Milot J, 43:73  
 Minamihisamatsu M,  
 38:61  
 Minowada J, 37:193  
 Miró R, 41:61  
 Mirro Jr J, 40:13  
 Mirto S, 37:127  
 Misawa S, 37:133  
 Mitani K, 39:299  
 Mitelman F, 37:61;  
 37:139; 37:209;  
 37:235; 39:29; 39:69;  
 39:191; 39:195;  
 39:227; 40:137;  
 40:149; 40:163;  
 40:171; 40:187;  
 40:203; 41:93; 42:27;  
 42:51; 42:143; 42:187  
 Miyazono K, 39:299  
 Moerman P, 42:243  
 Moertel CA, 39:253  
 Mogensen B, 37:179  
 Molenaar WM, 38:25;  
 38:33  
 Montaldi A, 37:263  
 Monteil M, 43:243  
 Moore L, 38:255  
 Moreno S, 38:133; 41:175  
 Morgan R, 37:269; 43:35  
 Morris CM, 42:9  
 Morton CC, 39:185;  
 41:115  
 Mrózek K, 38:215  
 Mufti GJ, 40:149  
 Mulder MP, 40:129  
 Muleris M, 38:249  
 Murli H, 42:273  
 Mulvihill JJ, 42:273  
  
 Naiman T, 40:65  
 Najfeld V, 43:103  
 Nakić M, 42:147  
 Narod SA, 38:261  
 Nayak BN, 39:99  
 Nederlof PM, 42:87  
 Nedoszytko B, 38:215  
 Neff JR, 38:83  
 Nelken B, 37:9; 42:307  
 Neto JB, 40:33  
 Neuhaus P, 39:65  
 Neumann HPH, 39:289  
 Neumann Y, 38:131  
 Nicoletti B, 40:135  
 Nieddu M, 37:49; 41:149  
 Nielsen KV, 39:103  
 Nilbert M, 37:61; 39:195;  
 42:51  
  
 Nishida-Umehara C,  
 40:47  
 Nishigaki H, 37:133  
 Noens L, 43:227  
 Nomura K, 37:273  
 Nordenson I, 38:297;  
 39:147  
 Nordlinger B, 38:249  
 Norton JD, 37:169  
 Nowell PC, 42:1  
 Nowotny H, 43:119  
  
 Ochi H, 43:131  
 Offit K, 37:85; 43:109  
 Ohama K, 43:79  
 Ohno H, 40:73  
 Ohtake K, 37:273  
 Ohyashiki JH, 37:193  
 Ohyashiki K, 37:193  
 Oláh E, 43:179  
 Oldigs M, 41:129  
 Olofsson K, 41:33  
 Oosterhuis JW, 40:129;  
 41:105  
 Orecchia G, 42:309;  
 43:89; 43:249  
 O'Reilly RJ, 43:67  
 Origone P, 43:51; 43:195  
 Osborn C, 38:9  
 Oshimura M, 38:271  
 Osinga J, 38:1  
 Ovanessoff S, 37:157  
 Oxley VE, 39:295  
 Ozawa N, 38:271  
  
 Paladini P, 43:95  
 Palka G, 39:139; 41:49  
 Palumbo AP, 39:77  
 Pandis N, 40:83  
 Paoli R, 37:49  
 Papanastasiou C, 40:83  
 Parmentier C, 41:139  
 Parruti G, 39:139; 41:49  
 Parry DM, 42:273  
 Parry SH, 39:295  
 Passarge E, 37:95  
 Pathak S, 37:55; 41:145  
 Patil SR, 39:157; 42:227  
 Paweletz N, 38:283;  
 42:75; 43:151  
 Pedersen MI, 41:185  
 Petković I, 39:203; 42:147  
 Pettenati MJ, 37:221  
 Philip P, 40:171  
 Piatt J, 37:269  
 Pierre RV, 40:149; 40:203  
 Pinkerton P, 40:105  
 Piva N, 37:29



- Pomier G, 42:67  
 Ponzio G, 37:79; 39:77  
 Popescu Nc, 42:157  
 Porfirio B, 43:95  
 Poth JL, 43:35  
 Preisler HD, 39:55  
 Price C, 37:293  
 Prieur M, 37:65; 38:205  
 Prigogina E, 40:171  
 Punnett HH, 41:123  
  
 Quanguang C, 37:85  
  
 Raap AK, 42:87  
 Raimondi SC, 40:13  
 Ramaekers FCS, 42:115  
 Ramirez GM, 38:115  
 Ramot B, 38:131  
 Ramzy I, 39:219  
 Ranganathan R, 43:67  
 Rao U, 37:281; 39:281;  
 43:39  
 Rappaport H, 37:201  
 Rassool F, 42:191  
 Ray M, 39:99  
 Rayevskaya GB, 37:39  
 Rebuttato AM, 43:57  
 Rechavi G, 38:131  
 Reeves BR, 40:149;  
 40:163; 40:187;  
 40:203  
 Reimers U, 41:129  
 Reiss R, 38:43  
 Renaud J, 39:35  
 Rey J, 38:133; 41:175  
 Reynaud J, 42:67  
 Richardson ME, 37:85  
 Richer CL, 40:55; 43:73  
 Richkind KE, 38:49  
 Ritchie E, 37:55  
 Rizzi R, 38:223  
 Rodhain J, 42:209  
 Roels HJ, 39:21  
 Rogatto SR, 40:33  
 Roser M, 41:129; 43:219  
 Rosti G, 42:191  
 Rowley JD, 37:1; 38:137;  
 40:149; 40:163;  
 40:171; 40:187;  
 40:203  
 Rozner E, 38:131  
 Rüdiger HW, 41:129;  
 43:219  
 Russell P, 38:13  
 Ruutu T, 40:149; 40:171;  
 40:203  
  
 Rydholm A, 37:61;  
 37:139; 39:227;  
 40:137; 42:27; 42:187  
  
 Sacchi S, 41:203  
 Saglio G, 42:191  
 Sakurai M, 40:187;  
 40:203  
 Salvidio E, 43:57  
 Sampaio DA, 41:71  
 Sampliner R, 42:281  
 Samson D, 37:293  
 Sanada I, 43:139  
 Sandberg AA, 37:157;  
 37:193; 37:269;  
 37:281; 38:145;  
 39:119; 39:125;  
 39:155; 39:281;  
 39:289; 40:1; 40:171;  
 41:99; 43:15; 43:35;  
 43:39  
 Sandros J, 39:153  
 Sanger WG, 38:83  
 Sansone R, 37:19  
 Santoro A, 37:127  
 Sapino A, 37:79  
 Sasaki M, 38:61; 40:47  
 Saura R, 37:285  
 Savary JB, 37:9  
 Savin E, 37:23  
 Sawyer J, 42:99  
 Scala D, 37:263  
 Scalise A, 43:103  
 Scappaticci S, 42:309;  
 43:89; 43:249  
 Scarpa RM, 41:149  
 Schaart G, 42:115  
 Scheithauer BW, 39:253  
 Schellhammer PF, 37:241  
 Schlegelberger B, 41:87  
 Schmidtke J, 37:141  
 Schmidt-Preuss U,  
 41:129  
 Schmoll H, 37:141  
 Schneider NR, 43:67  
 Scholde SC, 40:111  
 Schraffordt Koops H,  
 41:105  
 Schroeter D, 38:283  
 Schultz CG, 39:253  
 Schwartz MR, 39:219  
 Secker-Walker LM,  
 37:169; 40:163;  
 40:171  
 Seemanova E, 43:219  
 Selleri L, 38:101  
 Selypes A, 39:181  
 Senn J, 40:105  
  
 Seruca R, 41:105  
 Sessarego M, 37:19;  
 42:253; 43:51; 43:57;  
 43:195  
 Shabtai F, 38:43  
 Shapiro NI, 37:39  
 Sheibani K, 37:201  
 Shen M, 39:89  
 Sheppard DM, 38:49  
 Sherwood JB, 42:35  
 Shido T, 43:139  
 Shipley W, 39:141  
 Sleijfer DTh, 41:105  
 Smadja N, 42:55  
 Smith A, 38:13  
 Smith PJ, 38:121  
 Solberg Jr LA, 39:167  
 Somers KD, 37:241  
 Sotto JJ, 43:243  
 Speleman F, 39:21; 40:29  
 Spoudeas H, 37:293  
 Sreekantaiah C, 39:55;  
 39:119; 39:125;  
 39:281  
 Stamatellou M, 40:83  
 Stampfer MR, 37:249  
 Stanley WS, 39:233  
 Stella M, 37:263  
 Stenman G, 39:153  
 Sternberg A, 38:43  
 Sternes KL, 43:151  
 Stettner S, 37:55  
 Stock AD, 37:201  
 Strigini P, 37:19  
 Stupca PJ, 42:173  
 Stuppia L, 39:139; 41:49  
 Subias A, 41:61  
 Sugano H, 37:273  
 Sugiyama T, 40:73  
 Sumegi J, 42:295  
 Sunde L, 37:179  
 Surti U, 38:229  
 Svendsen LB, 39:245  
 Swansbury GJ, 40:149;  
 40:187; 40:203  
  
 Tagliafico E, 38:101  
 Tailor S, 40:89  
 Takaku F, 39:299  
 Takatsuki K, 43:139  
 Takino T, 37:133  
 Tamura T, 40:47  
 Tanaka K, 43:1  
 Taniwaki M, 37:133  
 Tanke HJ, 42:87  
 Tanzer J, 37:279  
 Tassinari A, 42:191  
 Taylor LD, 39:219

- Teare MD, 42:221  
 Tedeschi B, 40:135  
 Teerenhovi L, 41:1  
 Tefferi A, 39:167  
 Temperani P, 37:23;  
 38:101; 41:203  
 Testa JR, 43:1  
 Testoni N, 42:191  
 Teyssier JR, 37:103; 39:35  
 Thangavelu M, 37:1  
 Thompson EN, 43:211  
 Thompson PW, 39:143;  
 43:211  
 Tien HF, 39:89; 42:203  
 Tierney J, 38:75  
 Timmons CF, 41:79  
 Tomai G, 39:137  
 Tomasi P, 37:29  
 Torelli G, 38:101  
 Torelli U, 38:101  
 Toyama K, 37:193  
 Tran-Paterson R, 42:129  
 Travis LB, 42:173  
 Trent JM, 41:207; 42:281  
 Tribukait B, 42:27  
 Trivedi AH, 37:291  
 Troy K, 43:103  
 Trujillo JM, 42:287  
 Tsakanikas S, 40:83  
 Tuchman M, 42:99  
 Tura S, 42:191  
 Turc-Carel C, 43:39  
 Tyl E, 43:119  
  
 Uchino H, 40:73  
 Ueda K, 43:79  
 Unterkircher L, 41:79  
 Urabe A, 39:299  
 Usai E, 41:149  
  
 van Berlo RJ, 38:25;  
 38:33  
 Van Daele S, 40:29  
 Vandenberghe E, 42:209  
 Van Den Berghe H,  
 39:21; 40:29; 40:149;  
 40:171; 40:187;  
 40:203; 42:209;  
 42:243; 43:227  
 van der Flier S, 42:87  
 van der Hout AH, 38:1  
 van der Kwast TH,  
 42:115  
 van der Ploeg M, 42:87  
 van der Veen AY, 38:1  
 van Drunen E, 40:129  
 Van Dyke DL, 38:127  
 van Haaften-Day C, 38:13  
 Vanni R, 37:49; 41:149  
 Van Orshoven A, 42:209;  
 43:227  
 Vansover A, 38:131  
 Varshaver NB, 37:39  
 Vasselon C, 42:67  
 Vejerslev LO, 37:179  
 Vekemans M, 37:163  
 Vemuganti S, 42:227  
 Venuat AM, 41:139  
 Verma RS, 38:115; 39:25  
 Vernole P, 40:135  
 Versnel MA, 42:115  
 Vig BK, 38:283; 42:75;  
 43:151  
 Vimercati R, 43:51  
 Viola MV, 38:75  
 Vos A, 41:105  
  
 Wahlin A, 38:297; 39:147  
 Walen KH, 37:249  
 Walter TA, 39:289; 41:99;  
 43:15  
  
 Wang C, 39:89  
 Wang G, 42:107  
 Wang N, 41:185  
 Watanabe S, 43:131  
 Waziri MH, 39:157;  
 42:227  
 Wedell B, 37:215  
 Weichenthal M, 41:129;  
 43:219  
 Weidner N, 41:115  
 Weiss L, 38:127  
 Weitnauer L, 38:223  
 Wennerberg J, 37:235;  
 39:29; 39:69; 39:227  
 Whang-Peng J, 40:171  
 Whittaker JA, 39:143;  
 43:211  
 Wierda J, 38:33  
 Willard HF, 42:129  
 Willén H, 37:61; 37:139;  
 40:137; 42:51; 42:187  
 Willén R, 39:29  
 Williams DL, 40:13  
 Williams GJ, 40:187  
 Wilson HL, 41:79  
 Winberg CD, 37:201  
 Womer RB, 38:89  
  
 Yokota K, 43:79  
  
 Zaccaria A, 42:191  
 Zachee P, 42:209  
 Zaeri N, 41:123  
 Zandecki M, 42:307  
 Zech L, 41:87  
 Zóltowska Z, 38:215  
 Zucchini P, 38:101;  
 41:203  
 Zuschneid W, 39:65

---

## Subject Index to Volumes 37-43

---

- Acute lymphoblastic leukemia (ALL)  
ALL in relapse, 40:163  
CALLA gene on chromosome 3, 42:129  
chromosome changes in, 37:9; 40:163  
clinical correlations, 40:171  
dic(9;12)(p13;p11) in ALL, 42:307  
drug resistance, 41:256  
mixed lineage leukemia, 40:83  
Ph negative ALL preceding Ph+ CML, 39:147  
prognostic factors, 37:9; 40:163  
significance of karyotype, 40:171  
t(1;19)(q23;p13) in, 37:9  
t(2;8) in Burkitt leukemia and AIDS, 38:131  
t(9;12)(p13;q24) in ALL, 37:293  
t(17;19)(q11;q13) in, 37:9  
unrelated clones in mixed lineage leukemia, 40:83
- Acute megakaryoblastic leukemia (M7)  
possible M7 with t(10;17)(p13;q12), 39:45
- Acute monocytic (monoblastic) leukemia (AMoL, M5)  
secondary, chromosomes, 42:43  
t(3;8;17)(q27;p11;q12) in, 42:67  
t(9;11) in childhood M5, 40:13  
t(11;V) or del(11q) in childhood M5, 40:13  
+8 in a case, 40:47  
9q21-22 in M5, 39:55  
11q23 in childhood M5, 40:13
- Acute myeloblastic leukemia (AML, M1 and M2); see also Acute nonlymphocytic leukemia (ANLL)  
acquisition of primary changes, 40:105  
clinical significance of karyotype, 40:203  
cytogenetic studies, 40:187  
idic(X)(q13) in, 42:177  
inv(3) and abnormal thrombopoiesis, 39:167  
inv(16)(p13q22) and 5q- in a case with previous t(8;21), 40:105  
relapse and chromosomes, 40:187  
secondary, 42:43  
t(1;7)(p11;p11) in, 38:49  
t(5;16)(q33;q22) and eosinophilia in M1, 43:139  
t(6;9)(p23;q34) in, 42:212  
t(6;9)(p23;q34) in patients with sarcoidosis, 38:297  
t(8;16) and c-mos translocation, 37:221  
t(8;16)(q22;q24) in Down syndrome with M4, 37:221  
t(8;21) in childhood ANLL, 40:13  
+4 and dmin in, 39:295  
+4 in cases, 41:203, 43:211  
9q21-22 in AML, 39:55
- Acute myelomonocytic leukemia (AMMoL, M4)  
inv(3) and abnormal thrombopoiesis, 39:167  
inv(16) and +22: an association?, 43:119  
mixed lineage leukemia, 40:83  
t(1;7)(p11;p11) in, 38:49  
t(1;11)(q21;q23) in, 37:269  
t(6;9)(p23;q34) in, 42:212  
t(6;9)(p23;q34) in cases of sarcoidosis, 38:297  
t(8;16)(p11;p13) in a case following Hodgkin disease, 37:127  
unrelated clones in mixed lineage leukemia, 40:83  
+4 in cases, 43:211  
9q21-22 in M4, 39:55  
+20 in a case, 39:25  
11q23 in childhood M4, 40:13
- Acute nonlymphocytic leukemia (ANLL)  
childhood ANLL, 40:13  
chromosome changes in, 37:1; 40:13; 40:187; 42:43  
chromosome changes in APL and its variant, 37:263; 40:13  
chromosome changes in relapse, 40:187  
chromosomes 5 and 7, 38:261  
clinical significance of karyotype, 40:203  
del(11) in, 40:13  
del(16) in, 40:13  
der(5) in, 37:1  
inv(3) and abnormal thrombopoiesis, 39:167  
inv(16) and +22, 43:119



- inv(16) in, 40:13
- loss of Y in case with t(6;9), 39:81
- M6 in constitutional inv(4), 39:119
- occupation and ANLL, 38:261
- relapse and chromosomes, 40:187
- secondary: chromosomal differences in solid tumors vs hematologic states, 42:43
- secondary and chromosome changes, 37:1; 42:43
- t(1;7)(p11;p11) in, 38:49
- t(1;11)(q21;q23) in M4, 37:269
- t(5;7)(q11.2;p11.2) in, 37:1
- t(6;9)(p23;q34) in, 42:212
- t(6;9)(p23;q34) in 2 patients with sarcoidosis, 38:297
- t(8;16)(p11;p13) in t-ANLL following Hodgkin disease, 37:127
- t(8;16)(p11;p13) Table of cases in literature, 37:130
- t(8;16)(q22;q24) in M4 in Down syndrome, 37:221
- t(8;21) in, 40:13
- t(9;11) in, 40:13
- t(10;17)(p13;q12) in ANLL, 39:45
- t(11;V) in, 40:13
- t(15;17) in APL, 37:263; 40:13
- therapy related ANLL (t-ANLL), 37:1; 42:43
- +4 in cases, 41:205; 43:211
- 7 or 7q- in, 40:13
- 9q21-22 in ANLL, 39:55
- +14: a new entity in, 43:35
- +20 in a case of M4, 39:25
- +22 in ANLL, 43:119
- Acute promyelocytic leukemia (APL)
  - clinical studies in APL and variant (M3V), 37:263
  - cytogenetic studies in APL and variant (M3V), 37:263
  - t(11;17)(q13;q12) and t(7;12)(p15;p13) in a case of, 43:103
  - t(15;17) in, 37:263; 40:13
  - t(15;17) in childhood M3, 40:13
- Adamantinoma
  - chromosome changes, 42:187
  - translocations in, 42:187
- Adenoma(s)
  - chromosome of colonic, 37:285; 41:282, 283
  - polyps of colon, 37:285; 38:197; 41:282, 283, 284
  - tetraploidy in fibroblasts in family with, 39:245
- Adenomatous polyposis coli (APC); also see Familial polyposis coli
  - chromosome breakage in, 42:263
- Adipose tumors
  - chromosomes in lipoma, 37:281; 38:159; 39:281; 41:230, 292; 42:143
  - oncogene int-1 in, 42:143
- Anemia; see Refractory anemia
- Angioleiomyoma
  - chromosome changes in, 37:61
  - of ischiorectal fossa, 37:61
  - 13, +1-2 mar in, 37:61
- Angiosarcoma
  - complex karyotype in, 41:268
- Asbestos
  - effect of mesothelial cells, 41:33
  - induced chromosomal changes, 41:33
- Astrocytoma; see Glioma and Brain tumors
- B-cell
  - CLL, 41:43, 87; 43:143, 147
  - cytogenetics of murine lymphoma; 38:25
  - lymphoma in mouse; 38:25
- Basal cell epithelioma
  - cytogenetics of, 42:309
  - multiple clones in, 42:309
- Basophilia
  - in cases with t(6;9); 39:82
- bcr in leukemia
  - bcr rearrangement in Ph negative CML with t(9;9)(p13;q34), 43:51
  - bcr use for minimal disease in posttransplant CML; 43:67
  - in variant Ph translocations in CML, 37:169; 42:191
- Benign tumors
  - basosquamous papilloma of skin, 37:235
  - chromosome changes in, 37:110, 38:151
  - chromosome changes in an angioleiomyoma, 37:61
  - chromosome changes in leiomyoma, 37:49, 157
  - colonic polyps, 37:285
  - inv(12) in endometrial polyp, 41:99
  - lipoma, 37:281; 39:281
  - of cartilage, 38:83
- Bladder (urinary)
  - chromosome instability in patients with bladder cancer, 38:175
  - chromosomes in tumors of, 37:107; 38:175; 41:232; 42:135
  - cytogenetics, histopathology and tumor behavior, 41:232; 42:135
  - histologic grade and chromosomes, 42:135
  - marker chromosomes in cancer, 42:135
  - 21q22 deletion in cancer, 38:127
- Blast crisis (blastic phase) of CML
  - chromosomes in, 39:89

- myeloid crisis and +8, +19 and +21, 39:29
- near-haploidy in megakaryoblastic, 39:133
- Bone marrow
  - chromosomes in lymphoma, 37:85
  - fragile sites in leukemia, 43:131
  - NOR in murine tumors, 37:55
- Bone marrow transplantation (BMT)
  - cancer model, 41:256
  - cytogenetics in cancer with CML, 41:49; 42:253
  - follow-up in CML, 42:253
  - minimal disease in CML based on *bcr* analysis, 43:67
- Bone tumors
  - adamantinoma, 42:187
  - benign, cytogenetics, 41:272
  - giant-cell tumor, 38:161
  - karyotypes in osteosarcomas, 38:89
  - osteosarcomas, 38:89
- Book reviews
  - Catalog of Chromosome Aberrations in Cancer, 38:137
  - Principles and Practice of Pediatric Oncology, 42:313
- Bowen disease
  - t(9;12)(q32;q21) in, 43:249
- Brain and CNS tumors
  - changes in gliomas, 39:253; 41:175
  - chromosome anomalies in, 41:274, 275
  - cytogenetic follow-up of gliomas, 41:175
  - cytogenetics, 38:172, 39:253; 41:175, 226, 274, 275
  - der(11) in medulloblastoma, 38:255
  - fragile sites, 38:171
  - gene amplification in, 41:226
  - in von Hippel-Lindau disease, 42:227
  - metastasis of a large cell lung cancer, 39:181
  - oncogenes in glioblastoma cell lines, 38:172
  - pineoblastoma with 11q-, 39:125
- Breakage (of chromosomes)
  - induced by melphalan, 37:65
- Breakpoint cluster region; see *bcr*
- Breast tumors
  - adenocarcinoma metastatic to pleura, 39:219
  - c-erb B* in breast cancer, 38:186
  - c-neu* expression in cancer, 38:185
  - chemical-induced transformation, 37:249
  - chromosome changes in cancer, 38:184, 187
  - chromosome 11 in cancer, 38:185
  - chromosomes in a nonmalignant cell line, 39:103
  - chromosomes in transformed cells, 37:249
  - chromosomes 11, 13 and 17 in cancer, 38:185
  - familial cancer, linkage studies, 38:241
  - fragile sites, 41:247
  - HER-2/*neu* oncogenes in 41:219
  - interphase cytogenetics in cancer, 38:186
  - male, cancer in, 41:281
  - nonmalignant epithelium 39:103
  - protooncogene alterations in tumor cell lines, 41:263
- Burkitt lymphoma and leukemia (BL)
  - t(2;8) in AIDS associated BL, 38:131
- C-bands; also see Heterochromatin
  - in leukemia, 41:71
  - in preleukemia, 41:71
  - of chromosomes 1, 9, 16 and Y, 41:71
- Cancer
  - chromosome 1 changes in, 43:179
  - family syndrome, 38:75, 223
  - human gene map and, 41:215
  - loss of genetic information in, 41:220
  - protooncogene studies in cancer family, 38:75
  - registry, 41:216
  - t(2;22)(q21;q37) in family cancer, 38:223
- Cartilage
  - benign tumors of, 38:83
  - chromosome changes in tumors of, 38:83
  - chromosomes 2 and 13 in tumors of, 38:83
  - malignant neoplasms of, 38:83
  - t(2;13) in tumors of, 38:83
- Cell line(s)
  - cervical cancer, 38:53
  - gene amplification in v-src transformed rat fibroblasts, 41:266
  - lymphoma with *c-myc* changes, 40:73
  - malignant of Chinese hamster, 37:39
  - mammary cells, 37:249; 39:103
  - mesothelioma, 42:115
  - myeloid leukemia and TcR rearrangements, 37:193
  - non-malignant mammary epithelium, 39:103
  - ovarian cancer, 38:13
  - ovarian cancer, drug resistant, 39:35
  - prostatic, 37:241
  - retinoblastoma with *dmin* and *HSR*, 37:133
  - reversion to normal phenotype by SV40, 37:39
  - small cell lung cancer, 38:1

- testicular tumors, rearranged Y, 37:141
- xeroderma pigmentosum, 40:65
- Cell matrix receptors
  - in malignant cells, 41:19
  - VLA integrins, 41:19
- Centromere
  - DNA composition of, 43:153, 165
  - evolution of compound centromeres, 42:75
  - kinetochore formation, 38:283, 43:155
  - premature separation, 38:283
  - sequence of separation, 38:283; 43:157
  - structure and function in neoplasia, 43:151
- Cerebellar hemangioblastoma; also see Brain tumors
  - in von Hippel-Lindau disease, 42:227
- Cervix uteri; see also Uterus
  - cell lines, 38:53
  - chromosome 17 in cancer of, 37:230
  - cytogenetics of cell lines, 38:53
  - HPV-18 integration, 42:158
  - i(5p) in, 38:180
  - SCE levels in patients, 43:79
  - 17p- in a carcinoma, 37:229
- Chondrosarcoma; see Cartilage
  - chromosomes in extraskeletal myxoid, 38:83
  - complex cytogenetic changes, 41:115
  - extraskeletal with loss of alleles on chromosomes 10 and 22, 41:268
- Choriocarcinoma
  - chromosome changes in cell lines, 38:229
- Chromosome(s)
  - breaks and gaps induced by melphalan, 37:65
  - changes (induced), 37:65
  - del(1)(p12-13) in gastric leiomyosarcoma, 37:215
  - i(6p) in retinoblastoma, 37:95
  - inv(5) in lymphoma, 37:279
  - ring in MEN IIA S (Sipple S), 37:23
  - Y in testicular tumors, 37:141
  - 1 abnormalities in malignant diseases, 43:179
  - 1 in Wilms tumor, 43:203
  - 1, 3 and i(8q) in lung adenocarcinoma, 38:133
  - 1, 3, 5, 6, 8, 10, 11, 12, 17, 18 in solid tumors, 40:3
  - 1, 9, 16 C-bands, 41:71
  - 1p32-36, 6q21-25, 14, 9 and 11 in lymphoma, 37:85
  - 1q+ and 3q+ in MDS of a dysmorphic child, 38:9
  - 2 and 13 in cartilage tumors, 38:83
  - 2p- and 22q- in Merkel cell tumor, 38:43
  - 3 in leukemia with abnormal thrombopoiesis, 39:167
  - 3p restriction map, 42:295
  - 3q- in CMMoL, 37:29
  - 5 and 7 in ANLL and occupation, 38:261
  - 5 in MDS and t-ANLL, 37:1
  - 5, 7, 11 and 17 changes induced by melphalan, 37:65
  - 5q- in CMMoL, 37:29
  - 6p in lipoma, 37:281
  - 7 in MDS and t-ANLL, 37:1
  - +8 in CMMoL, 37:29
  - 8p11 in M5, 42:67
  - 9q11 and melphalan, 37:65
  - 10 in glioblastoma, 41:227
  - 11 in human tumors, 38:162
  - 11q- in CMMoL, 37:29
  - 12 in testicular tumors, 40:129
  - 13 in lipoma, 39:281
  - 13 in osteosarcoma, 38:89
  - 16 in polymorphism in CML, 39:139
  - 17 in cervix cancer (Table), 37:230
  - 17p- in cervical cancer, 37:229
  - 18 and 22 in leiomyosarcoma, 37:215
  - 19 in ALL, 37:9
  - 21q22 in bladder cancer, 38:127
  - 22 in leiomyoma of uterus, 37:49
  - 22 in meningioma, 40:33
  - 22 in Merkel cell tumor, 38:43
- Chromosome changes
  - asbestos and mesothelial cells, 41:33
  - chromosome 17 in cervical cancer, 37:230
  - in a congenital fibrosarcoma, 39:21
  - in a lipoma, 37:281
  - in a nasal papilloma, 39:29
  - in ALL, 37:9
  - in ALL in relapse, 40:163
  - in an angioleiomyoma, 37:61
  - in ANLL, 37:1
  - in ANLL in relapse, 40:187
  - in APL, 37:263
  - in bladder cancer, 42:135
  - in cartilage tumors, 38:83
  - in cervical cancer cell lines, 38:53
  - in childhood ANLL, 40:13
  - in choriocarcinoma cell lines, 38:229
  - in CLL, 43:143
  - in CML, 37:163, 169; 38:61, 115; 39:89; 42:253
  - in CMMoL, 37:29
  - in colonic polyps 37:285
  - in Ewing tumor, 37:79
  - in gastric leiomyosarcoma, 37:215
  - in gliomas, 39:253; 40:111
  - in Hodgkin disease, 37:201



- in kidney tumors, 43:15
- in leiomyosarcoma, 43:39
- in MDS, 37:1
- in mediastinal germ cell tumor, 42:243
- in melanoma, 41:185
- in meningioma, 40:33
- in mesothelioma, 42:115
- in moles, 37:179
- in murine lymphoma, 38:25, 33
- in myelodysplasia, 40:149
- in myelofibrosis, 38:101
- in neuroblastoma, 41:153 (review)
- in non-Hodgkin lymphoma, 37:85
- in osteosarcomas, 38:89
- in ovarian cancer, 43:1
- in ovarian cancer cell line, 38:13
- in pancreatic cancer, 37:209
- in papilloma (skin), 37:235
- in pleural metastases (lung, breast, stomach), 39:219
- in preleukemia, 40:149; 42:1
- in prostatic cell lines, 37:241
- in RAEB-t, 42:55
- in renal cell cancer, 43:15
- in retinoblastoma, 37:95; 42:203
- in secondary leukemia, 37:1; 42:43
- in secondary leukemia and MDS, 43:227
- in skin tumors, 39:227
- in solid tumors, 37:103; 40:3
- in squamous cell carcinoma of skin, 39:69
- in subacute myelomonocytic leukemia
  - in twins, 38:205
- in synovial sarcoma, 38:215
- in testicular tumor, 41:105
- in therapy related MDS and ANLL, 43:227
- in thrombocythemia, 43:57
- in thyroid adenomas, 39:65
- in uterine leiomyomas, 37:49, 157
- induced by melphalan, 37:65
- MEN IIA S (Sipple S); 37:23
- radiotherapy, 41:61
- Chronic lymphocytic leukemia (CLL)
  - chromosome changes, 41:13, 87; 43:143
  - oncogenes and CLL, 43:147
  - reduced fragile sites expression, 39:99
  - transient inv(14)(q11q32), 41:87
- Chronic myelocytic (myeloid) leukemia (CML)
  - bcr analysis, 37:169; 38:67; 42:191
  - BCR-ABL expression and its determinants, 42:9, 287
  - BCR-ABL rearrangements in CML, 42:287; 43:195
  - bone marrow transplantation and cytogenetics, 41:49; 42:253
  - c-abl and c-sis in variant Ph, 38:61
  - changes during course of blastic phase, 39:299
  - chromosome changes in, 37:169; 38:61, 115; 39:89; 42:191, 253
  - cytogenetics in bone marrow transplantation, 41:49; 42:253
  - heterochromatin polymorphism of chromosome 16, 39:139
  - i(17q) in Ph- CML, 43:195
  - in Taiwan, 39:89
  - in transformation, 39:89
  - near-haploidy in megakaryoblastic crisis, 39:133
  - Ph negative ALL preceding Ph+ CML, 39:147
  - Ph negative, bcr+ and t(9;9)(p13;q34), 43:51
  - Ph negative, molecular studies, 43:195
  - pulsed-field gel electrophoresis and BCR-ABL, 42:287
  - t(1;9)(p32;q34) in Ph negative CML, 37:169
  - t(3;5)(p21;q31) in Ph negative case, 37:163
  - t(3;21)(q26.2;q22) in, 39:143
  - variant Ph translocations, 37:169; 38:61, 115; 42:191
- Chronic myelomonocytic leukemia (CMML); also see Myelodysplastic syndromes
  - chromosome changes in, 37:29
  - del(3)(q21) in megakaryocytic cellular fraction, 37:29
  - del(13)(q23) in monocytic cellular fraction, 37:29
  - different cellular populations, 37:29
  - idic(X)(q13) in, 42:177
  - 5q- and +8 in all cellular fractions, 37:29
- Colon; see Large bowel
- Congenital leukemia
  - chromosome changes in, 37:19
  - ins(6;1)(p21;p13p36) in, 37:19
- Constitutional chromosome abnormalities
  - in neuroblastoma patients, 41:155
  - inv(4) and ANLL, 39:119
  - t(4;15) in female with lung cancer, 41:287
  - t(8;12)(q23;q11) and multiple malignancies, 41:242
- Cytogenetic changes
  - asbestos and mesothelial cells, 41:33
  - chromosome 17 in cervical cancer, 37:230
  - in a congenital fibrosarcoma, 39:21
  - in a lipoma, 37:281
  - in a nasal papilloma, 39:29
  - in ALL, 37:9

in ALL in relapse, 40:163  
 in an angioleiomyoma, 37:61  
 in ANLL, 37:1  
 in ANLL in relapse, 40:187  
 in APL, 37:263  
 in bladder cancer, 42:135  
 in cartilage tumors, 38:83  
 in cervical cancer cell lines, 38:53  
 in childhood ANLL, 40:13  
 in choriocarcinoma cell lines, 38:229  
 in CLL, 43:143  
 in CML, 37:163, 169; 38:61, 115; 39:89; 42:253  
 in CMMoL, 37:29  
 in colonic polyps 37:285  
 in Ewing tumor, 37:79  
 in gastric leiomyosarcoma, 37:215  
 in gliomas, 39:253; 40:111  
 in Hodgkin disease, 37:201  
 in kidney tumors, 43:15  
 in leiomyosarcoma, 43:39  
 in MDS, 37:1  
 in mediastinal germ cell tumor, 42:243  
 in melanoma, 41:185  
 in MEN IIA S (Sipple S), 37:23  
 in meningioma, 40:33  
 in mesothelioma, 42:115  
 in moles, 37:179  
 in murine lymphoma, 38:25, 33  
 in myelodysplasia, 40:149  
 in myelofibrosis, 38:101  
 in neuroblastoma, 41:153 (review)  
 in non-Hodgkin lymphoma, 37:85  
 in osteosarcomas, 38:89  
 in ovarian cancer, 43:1  
 in ovarian cancer cell line, 38:13  
 in pancreatic cancer, 37:209  
 in papilloma (skin), 37:235  
 in pleural metastases (lung, breast, stomach), 39:219  
 in preleukemia, 40:149; 42:1  
 in prostatic cell lines, 37:241  
 in RAEB-t, 42:55  
 in renal cell cancer, 43:15  
 in retinoblastoma, 37:95; 42:203  
 in secondary leukemia, 42:43  
 in secondary leukemia and MDS, 43:227  
 in secondary leukemia (t-ANLL), 37:1  
 in skin tumors, 39:227  
 in solid tumors, 37:103; 40:3  
 in squamous cell carcinoma of skin, 39:69  
 in subacute myelomonocytic leukemia  
   in twins, 38:205  
 in synovial sarcoma, 38:215  
 in testicular tumor, 41:105

in therapy related MDS and ANLL, 43:227  
 in thrombocythemia, 43:57  
 in thyroid adenomas, 39:65  
 in uterine leiomyomas, 37:49, 157  
 induced by melphalan, 37:65  
 radiotherapy, 41:61

# Deletions

del(X) in hematologic disorders, 42:173  
 del(7)(q21.2q31.2) in leiomyoma, 42:51  
 del(10)(q24) in cervical cancer, 41:232  
 del(11) in secondary ANLL, 42:43  
 del(17p) in secondary ANLL, 42:43  
 deletions in choriocarcinoma cell lines, 38:229  
 deletions in lymphoma, 37:85  
 gene amplifications, 41:220  
 in AML (ANLL), 40:187; 43:227  
 in ANLL in relapse, 40:187, 201  
 in childhood ANLL, 40:13  
 in kidney tumors, 43:15  
 in mesothelioma, 42:121  
 in ovarian cancer, 43:1  
 in RAEB-t, 42:55  
 in RCC, 43:15  
 in secondary ANLL, 43:227  
 induced by melphalan, 37:65  
 1p- in neuroblastoma, 41:217; 42:147  
 2q- in a uterine leiomyoma, 37:50  
 3q- in CMMoL, 37:29  
 5q- in CMMoL, 37:29  
 5q- in secondary ANLL, 42:43  
 6q- in salivary gland adenocarcinoma, 39:153  
 6q- in thymoma, 41:93  
 7q- in secondary ANLL, 42:43  
 7q- in uterine leiomyoma, 37:157  
 11q- in CMMoL, 37:29  
 11q- in pineoblastoma, 39:125  
 22q- in Merkel cell tumor, 38:43

# Derivative chromosomes

der(X) in osteosarcoma, 42:30  
 der(1) in a retinoblastoma, 37:96  
 der(1) in CML, 39:92  
 der(1) in polycythemia vera, 40:121  
 der(1), der(6), der(11) in squamous cell carcinoma of skin, 39:72  
 der(2) in CLL, 41:89  
 der(3) and der(5) in MDS, 38:9  
 der(3) in a fibrosarcoma, 37:139  
 der(3) in a lymphoma, 37:279  
 der(4) in uterine leiomyoma, 37:50  
 der(5) in a fibrosarcoma, 37:139  
 der(5) in MDS and t-ANLL, 37:1  
 der(8) in t-ANLL, 37:4

- der(9), der(20), der(7), der(21), der(17),  
der(11), der(14) in childhood ANLL,  
40:13
- der(11) in CML, 39:174
- der(11) in medulloblastoma, 38:255
- der(12) in t-ANLL, 37:4
- der(16) in Ewing sarcoma, 41:269
- der(19) in ALL, 37:9
- derivative chromosomes in  
choriocarcinoma cell lines, 38:229
- derivative chromosomes in lymphoma,  
37:85
- in AML (ANLL), 40:187; 43:227
- in ANLL in relapse, 40:187
- in gliomas, 40:111
- in kidney tumors, 43:15
- in lipoma, 42:144
- in mesothelioma, 42:121
- in ovarian cancer, 43:1
- in RCC, 43:15
- in secondary ANLL, 42:45; 43:227
- Dicentric chromosomes  
in squamous cell carcinoma, 40:95
- in xeroderma pigmentosum, 40:95
- jumping end-to-end dicentrics, 40:95
- Digestive tract  
chromosome changes in tumors of,  
37:108
- DNA studies  
bcr studies in CML, 37:169; 38:61
- c-abl and c-sis, 38:61
- c-mos in t(8;16), 37:221
- c-myc and n-myc in small cell lung  
cancer, 38:1
- c-myc in lymphoma cell line, 40:73
- CALLA gene on chromosome 3, 42:129
- flow cytometry in melanoma cases,  
39:245
- flow cytometry in moles, 37:179
- identification of rearranged Y in  
testicular tumors, 37:141
- in cancer family, 38:75
- in leukemia, 40:217
- in myelofibrosis, 38:101
- in Ph-, bcr+ CML, 43:51
- in posttransplant CML using bcr, 43:67
- in retinoblastoma, 37:95, 133
- in situ hybridization of PH, 38:61
- in Wilms tumor, 38:121, 43:203
- instability of hepatitis B viral, 37:273
- N-myc in retinoblastoma, 37:133
- of chromosome 6, 37:95
- protooncogene studies in cancer family,  
38:75
- pulsed-field gel electrophoresis of  
BCR-ABL in CML, 42:287
- restriction maps of 3p, 42:295
- RFLP in moles, 37:179
- RFLP in testicular tumors, 40:129
- Double minute chromosomes (dmin)  
c-myc and dmin, 41:236
- in AML (M2) with +4, 39:295
- in cancer of prostate, 39:191
- in retinoblastoma, 37:96, 133
- Down syndrome  
case with Ewing tumor, 37:79
- t(8;16)(q22;q24) in M4, 37:221
- t(11;22) in Ewing tumor, 37:79
- Drug(s) effects  
and secondary leukemia, 37:65
- chromosome rearrangements induced by  
melphalan, 37:65
- melphalan, 37:65
- on chromosomes in polyposis coli,  
42:623
- Duplication (chromosome)  
dup(11) in lymphoma, 37:91
- in childhood ANLL, 40:13, 22
- in choriocarcinoma cell lines, 38:229
- Dysgerminoma  
i(12p) in a tumor, 38:180
- Effusions  
chromosomes in cancer, 38:191
- Embryonal tumors  
chromosome changes in, 37:109
- Endometrial tumors; see Uterus
- Epidermal carcinoma  
cell line, 38:157
- Epitheloid sarcoma  
1p- in, 41:267
- Erythroleukemia (M6)  
in a patient with constitutional inv(4),  
39:119
- inv(3) and abnormal thrombopoiesis,  
39:167
- secondary, 42:43
- Esophagus  
Barrett's condition, 42:281
- chromosome changes in Barrett's,  
42:281
- Ewing tumors  
chromosome changes in, 37:79; 38:166,  
167; 41:269
- der(16) in, 41:269
- extraskeletal, 37:79
- in Down syndrome, 37:79
- t(1;13)(q23;q24) in, 41:269
- t(11;22)(q24;q21) in, 37:79
- Familial cancer  
breast-ovarian cancer, 38:241
- gall bladder, 39:141
- genetic linkage studies, 38:241



- germ cell tumors in Li-Fraumeni syndrome, 42:221
- Li Fraumeni syndrome, 42:221
- melanoma, 39:233
- protooncogene studies in, 38:75
- Familial polyposis coli (FPC)
  - chromosome breakage in, 42:263
  - chromosome changes in, 38:249; 41:282
  - cytogenetic studies in adenocarcinoma, 38:249
- Fibroma
  - angiofibromas, 41:271
  - chondromyxoid (chromosomes), 38:83
  - Dupuytren's fibroma, 41:270
- Fibrosarcoma
  - chromosome changes in, 37:139; 39:21; 40:137
  - congenital, 39:21
  - karyotypic features in a recurrence
    - separate from those in a metastasis, 37:139
  - translocations in, 37:139
  - +8,+11,+17,+20 in infantile fibrosarcoma, 40:137
- Fragile sites
  - chromosome breaks, oncogenes and cancer breakpoints, 41:247
  - common in lung cancer, 42:107
  - fluorodeoxyuridine and bromodeoxyuridine expression of, 41:41
  - fra(3)(p14.2) expression in patients with lung cancer, 43:95
  - HPV viral integration and, 42:160
  - in breast cancer, 41:247
  - in families with von Hippel-Lindau disease, 39:157
  - in leukemia patients, 43:131
  - in lung cancer patients, 42:107
  - no correlation with breakpoints in cancers of mouse and rat, 41:246
  - reduced expression in B-cell CLL, 39:99
  - 1p13.1 in neuroblastoma patients, 40:135
  - 3q21, 11p11, 11q13 fragility in leukemia and anemia, 40:47
- Gall bladder
  - cancer, familial, 39:141
- Gastric tumors; see Stomach
- Gene(s); see DNA studies and Molecular studies and Oncogenes
- Genetics
  - of cancer, 41:220
  - of colon cancer, 41:221
  - of kidney cancer, 41:221
  - of lung cancer, 41:225
  - of neuroblastoma, 41:153
- Genitourinary tumors; see Bladder and Kidney and Prostate Germ cell tumors; also see Testes
  - i(12p) in mediastinal tumor, 42:243
  - in Li-Fraumeni cancer family syndrome, 42:221
  - testicular and ovarian, 42:221
- Glioma(s) and Glioblastoma
  - c-myb amplification in glioblastoma, 41:240
  - chromosome changes in, 39:253; 40:111; 41:175, 278
  - chromosome 10 in glioblastoma, 41:227
  - cytogenetic and molecular studies in, 38:169; 39:253
  - cytogenetic follow-up, 41:175
  - loss of heterozygosity in glioblastoma, 41:227
  - resistance to drugs, 41:254
  - transplanted in athymic mice, 40:111
- Hamartoma
  - cytogenetics in liver, 40:29
  - liver, mesenchymal, 40:29
  - t(15;19)(q15;q13) in, 38:168; 40:29
- Hamster
  - cell line, 37:39; 38:271
  - Chinese hamster malignant cell line, 37:39
  - karyotypic changes in Syrian hamster cells (immortal and tumorigenic), 38:271
  - reversion to normal phenotype induced by SV40, 37:39
  - Syrian hamster cells treated with DES, 38:271
- Head and neck tumors
  - radioresistance and chromosomes 1, 5 and 14, 41:254
  - squamous cell carcinoma, 41:292
- Hepatocellular tumors or hepatoblastoma; see Liver tumors
- Heterochromatin
  - of chromosome 16 in CML, 39:139
- Heterozygosity
  - loss at 3p in renal cancer, 39:289
  - loss in glioblastoma, 41:227
  - loss of genetic information, 41:220
  - of 13q in retinoblastoma, 43:73
- Histiocytoma
  - malignant fibrous, DNA sequence amplification, 41:240
- Hodgkin's disease (HD)
  - ANLL following, 37:127
  - cytogenetic studies in, 37:201; 41:12; 43:109

- molecular studies in, 43:109
- t(8;16) in ANLL secondary in Hodgkin disease, 37:127
- TCR studies in, 43:109
- Homogeneously staining regions (HSR) and dmin in retinoblastoma, 37:133
- in ovarian cell line, 38:15
- in prostatic cell line, 37:241
- in retinoblastoma, 43:73
- in retinoblastoma cell line, 37:133
- in small cell lung cancer cells, 38:1
- in tumors using restriction endonucleases, 38:155
- N-myc amplification in, 37:133
- Homozygosity
- in glioblastoma, 41:227
- loss of 3p in renal cancer, 39:289
- 13q in retinoblastoma, 43:73
- Hydatidiform moles
- complete and incomplete, 37:179
- cytogenetic studies in, 37:179
- different cell populations in, 37:179
- DNA studies in, 38:184
- RFLP, flow cytometric, cytogenetic, HLA and morphologic studies, 37:179
- Immunophenotyping
- in situ hybridization, 41:1
- of aneuploid cells, 41:1
- In situ hybridization
- c-abl, c-sis and bcr in CML, 38:61
- der(1)t(1;9) in PV, 40:121
- detection of changes in interphase nuclei, 41:236; 42:87
- high resolution banding and, 41:245
- in solid tumors, 38:154, 155
- of variant Ph translocations, 38:61
- Insertions
- der ins(1;12)(q21;p13q24.3) in uterine leiomyoma, 37:50
- in ANLL, 40:200
- in childhood ANLL, 40:13
- in choriocarcinoma cell lines, 38:229
- in lipoma, 42:144
- ins(6)(p21;p13p36) in congenital leukemia, 37:19
- ins(6;3)(p21;q21q26.2) in ANLL, 39:175
- Interphase cytogenetics; see In situ hybridization
- Inversions
- constitutional inv(4) and ANLL, 39:119
- in ANLL, 40:200; 43:227
- in RAEB-t, 42:55
- in secondary leukemia, 43:227
- inv(X), inv(5) and inv(18) in mesotheliomas, 42:121
- inv(2)(p25q13) in a thymoma, 41:93
- inv(3), acute leukemia and abnormal thrombopoiesis, 39:167
- inv(5)(q13q34) in lymphoma, 37:279
- inv(12)(p11.2q13) in endometrial polyp, 41:99
- inv(14)(q11q32), transient, in CLL, 41:87
- inv(16) in childhood ANLL, 40:13
- inversion in lipoma, 42:144
- Isochromosomes
- i(X)(q13) in hematologic disorders, 42:173
- i(6p) in retinoblastoma, 37:95
- i(8q) in lung adenocarcinoma, 38:133
- i(12p) in mediastinal germ cell tumor, 42:243
- i(12p) in testicular tumors, 38:178; 40:119; 41:105
- i(17q) in CML, 38:63; 39:89
- i(17q) in Ph- CML and MPS, 43:195
- idic(X)(q13) in hematologic disorders, 42:175, 177
- in ANLL, 40:201
- in choriocarcinoma cell lines, 38:229
- mechanisms of i(6p), 37:95
- Kaposi sarcoma
- cytogenetic changes in, 38:193
- Karyotypes and karyotypic abnormalities
- asbestos and mesothelial cells, 41:33
- chromosome 17 in cervical cancer, 37:230
- in a congenital fibrosarcoma, 39:21
- in a lipoma, 37:281
- in a nasal papilloma, 39:29
- in ALL, 37:9
- in ALL in relapse, 40:163
- in an angioleiomyoma, 37:61
- in ANLL, 37:1
- in ANLL in relapse, 40:187
- in APL, 37:263
- in bladder cancer, 42:135
- in cartilage tumors, 38:83
- in cervical cancer cell lines, 38:53
- in childhood ANLL, 40:13
- in choriocarcinoma cell lines, 38:229
- in CLL, 43:143
- in CML, 37:163, 169; 38:61, 115; 39:89; 24:253
- in CMMoL, 37:29
- in colonic polyps 37:285
- in Ewing tumor, 37:79
- in gastric leiomyosarcoma, 37:215
- in gliomas, 39:253; 40:111
- in Hodgkin disease, 37:201
- in kidney tumors, 43:15
- in leiomyosarcoma, 43:39
- in MDS, 37:1
- in mediastinal germ cell tumor, 42:243

- in melanoma, 41:185
- in MEN IIA S (Sipple S), 37:23
- in meningioma, 40:33
- in mesothelioma, 42:115
- in moles, 37:179
- in murine lymphoma, 38:25, 33
- in myelodysplasia, 40:149
- in myelofibrosis, 38:101
- in neuroblastoma, 41:153 (review)
- in non-Hodgkin lymphoma, 37:85
- in osteosarcomas, 38:89
- in ovarian cancer, 43:1
- in ovarian cancer cell line, 38:13
- in pancreatic cancer, 37:209
- in papilloma (skin), 37:235
- in pleural metastases (lung, breast, stomach), 39:219
- in preleukemia, 40:149; 42:1
- in prostatic cell lines, 37:241
- in RAEB-t, 42:55
- in renal cell cancer, 43:15
- in retinoblastoma, 37:95; 42:203
- in secondary leukemia, 42:43
- in secondary leukemia and MDS, 43:227
- in secondary leukemia (t-ANLL), 37:1
- in skin tumors, 39:227
- in solid tumors, 37:103; 40:3
- in squamous cell carcinoma of skin, 39:69
- in subacute myelomonocytic leukemia in twins, 38:205
- in synovial sarcoma, 38:215
- in testicular tumor, 41:105
- in therapy related MDS and ANLL, 43:227
- in thrombocythemia, 43:57
- in thyroid adenomas, 39:65
- in uterine leiomyomas, 37:49, 157
- induced by melphalan, 37:65
- radiotherapy, 41:61
- Kidney**
  - adenomas, 43:15
  - cancer in von Hippel-Lindau disease, 39:289
  - chromosomes in normal tissue from cases with RCC, 37:289
  - chromosomes in tumors of, 37:108; 38:173; 41:283, 288; 42:227; 43:15
  - loss of DNA sequences in RCC, 41:221
  - loss of heterozygosity at 3p in renal cancer, 39:289
  - model for renal cell tumor?, 38:173
  - nephroblastoma with hyperdiploidy, 41:79
  - onocytoma, 38:174; 41:288; 43:15, 27
  - renal cell cancer in von Hippel-Landau disease, 42:227, 43:15
  - RFLP studies in Wilms tumor, 38:121
  - t(3;8) in hereditary RCC, 38:174; 43:15
  - t(10;17)(q22;p13) in clear cell sarcoma, 41:123
  - transitional cell carcinoma, 41:288; 43:27
  - translocations in tumors, 43:21, 22
  - Wilms tumor in adult, 38:121; 42:35
  - 3p and loss of heterozygosity, 38:173, 174; 43:15
  - +7 in transitional cell carcinoma, 41:149
- Kinetochores; also see Centromere**
  - characteristics, 43:155
  - compound kinetochores, 43:168
  - formation and DNA replication, 38:283
  - in dicentric chromosomes, 38:283
  - proteins, 43:159
- Large bowel**
  - adenocarcinoma in FPC family, 38:249
  - adenomatous polyps, 37:285; 38:197; 41:282, 283, 284
  - c-erb 2 in, 38:196
  - c-K-ras in, 38:195
  - chromosomes in polyps, 37:285; 41:282, 283
  - chromosomes 5 and 7 in cell line of cancer, 41:221
  - cytogenetic studies in cancer, 38:195, 196, 197, 198, 249; 41:282, 284
  - loss of chromosome 5 alleles, 38:197
  - tetraploidy in fibroblasts of cases, 39:245
  - +12, +14 and i(1q) in cancer, 42:91
- Leiomyoma**
  - chromosome 7 in, 38:183
  - cytogenetics of, 38:183; 41:279
  - no changes in c-int1, gli or col2A1 in leiomyoma with t(12;14), 39:195
  - t(1;6) and del(7) as separate anomalies in, 42:51
  - t(12;14)(q14-15;q23-24) in, 38:183
  - uterine, 37:49; 38:183
  - uterine with both t(12;14) and del(7), 37:157
- Leiomyosarcoma**
  - cell line with ?21q-, 41:145
  - chromosome abnormalities in a gastric, 37:215; 43:39
  - colonic, 43:39
  - cytogenetic changes in, 37:215; 43:39
  - gastric, 37:215; 43:35
  - retroperitoneal, 43:39
  - small bowel, 43:39
  - subgroup within, 43:39
  - uterine, 43:39



- Leukemia(s); also see Acute lymphoblastic leukemia (ALL), Acute nonlymphocytic leukemia (ANLL), Congenital leukemia, Secondary leukemias (t-ANLL), Chronic myelocytic (myeloid) leukemia (CML), Chronic myelomonocytic leukemia (CMMoL)  
bone marrow fragile sites, 43:131  
C-bands in, 41:71  
chromosome 1 changes in, 43:179  
cytogenetics of mixed lineage, 40:83  
high resolution technique in, 41:248  
mixed lineage, 40:83
- Linkage studies  
in familial breast-ovarian cancer, 38:241
- Lipoma  
chromosome changes in, 39:281; 41:230, 292  
chromosome 13 in lipoma, 39:281  
cytogenetic subgroups, 41:230  
oncogene *int-1* not rearranged in, 42:143  
6p in lipoma, 37:281; 38:159  
12q13-15 in lipoma, 42:143
- Liver tumors  
cytogenetics in hepatocellular cancer, 41:284  
hepatoblastoma, cytogenetic changes, 41:285, 286  
hepatoblastoma with +20, 41:285  
molecular studies in hepatoblastomas, 41:286
- Lung  
adenocarcinoma, 38:133  
adenocarcinoma metastatic to pleura, 39:219  
c-myc and n-myc in small cell lung cancer, 38:1  
cancer in a woman with a constitutional t(Y;15), 41:287  
chromosome anomalies in patients with cancer, 41:107  
chromosome changes in tumors of, 37:108; 38:199, 202, 203; 41:287  
comparison with squamous cell carcinoma cell line, 41:264  
detection of changes in normal tissue next to cancer with PCC, 41:251  
DNA studies in cancer, 38:198  
drug resistance, 41:256  
fra(3p14.2) in patients with cancer, 38:202; 43:95  
fragile sites (common) in patients with cancer, 41:107  
genetic lesions in cancer, 41:225  
HSR in small cell lung cancer, 38:1  
large cell cancer, metastasis to brain, 39:181  
molecular studies in, 38:199, 200  
myc in SCLC, 38:201  
non-small cell center, 41:287  
susceptibility and chromosome changes, 41:105  
1, 3 and i(8q) in adenocarcinoma, 38:133  
3p deletions in cancer, 38:201, 202  
7B2 gene in lung cancer, 41:260
- Lymphoma  
c-myc change in cell line without 8q24 involvement, 40:73  
chromosome changes in non-Hodgkin, 37:85; 41:13  
chromosome 9 and pulmonary involvement, 37:85  
chromosomes and sites of lymphoma involvement, 37:85  
inv(5) in, 37:279  
morphometric aspects of large cell lymphoma, 41:259  
mouse, B-cell, 38:25  
mouse, homing pattern, 38:33  
sites of involvement and chromosome changes, 37:85  
T-cell, changes in, 41:13  
t(13;17)(q12-14;p12-13) in lymphocytic lymphomas, 43:243  
1p32-36 and marrow involvement, 37:85  
6q22-24 and marrow involvement, 37:85  
-11 and bone involvement, 37:85  
14q22-24 and splenic involvement, 37:85
- Malignant fibrous histiocytoma  
DNA sequence amplification, 41:240
- Mammary cells and tumors; see Breast
- Marker(s)  
chromosomes in ovarian cancer cell line, 38:13  
in osteosarcomas, 38:89
- Medulloblastoma  
chromosome changes in, 41:228  
der(11)t(8;11)(q11;p11) in, 38:255
- Megakaryocytes  
del(3)(q21) in CMMoL, 37:29
- Melanoma  
c-myc and flanking regions in, 41:238  
chromosome changes (drug induced) in lymphoblasts, 39:233  
chromosome changes in, 37:108; 38:156, 158; 41:185, 280  
chromosome evolution, 41:185, 280  
familial, 39:233  
historical aspects, 42:153  
multiple lesion, cytogenetics, 41:253  
NOT-1 and 6q in, 41:261  
premalignant lesions of, 41:280

- progression and metastases, 41:185
- UV induced micronuclei and SCE in fibroblasts, 41:129
- MEN IIA
  - chromosome 10 in, 38:188
  - ring chromosome in Sipple S, 37:23
- Meningioma
  - chromosome changes in, 38:169, 170; 40:33; 41:277
  - chromosomes and pathology, 38:169, 170; 40:33; 41:277
  - fragile sites, 38:171
  - karyotypic evolution, 40:33; 41:279
  - malignant meningioma, 41:279
  - Merkel cell tumor in patient with previous meningioma, 38:43
  - molecular studies in, 38:170; 41:266
  - restriction mapping of 22q region, 41:266
- Merkel cell carcinoma
  - chromosome changes in, 38:43; 41:265
  - in patient with meningioma, 38:43
  - t(10;17)(q23;q21) in, 41:265
- Mesothelioma
  - c-sis and other genes in, 38:204
  - cell lines, 42:115
  - cytogenetic analysis, 38:200, 204; 41:293; 42:115
  - effects of asbestos on cells, 41:33
  - 3p changes in mesothelioma, 38:203
- Metastatic tumors
  - chromosomes in metastatic brain tumor, 39:181
  - large cell lung cancer to brain, 39:181
- Methods
  - analysis of colonic polyps, 37:285
  - aprotinin in tumor growth in vitro, 41:265
  - factor analysis of digital images, 41:245
  - for tumors, 41:262
  - in situ hybridization, 42:87
  - interphase in situ hybridization, 42:87
  - of solid tumor analysis, 37:104
  - pulsed-field gel electrophoresis, 42:287
  - synchronization of cultured retinoblastoma cells, 40:55
  - 1000 band resolution, 40:55
- Micronuclei
  - UV induced in fibroblasts of melanoma cases, 41:129
  - UV induced in xeroderma pigmentosum heterozygotes, 43:221
- Molecular studies
  - bcr analyses on CML, 37:169; 38:61; 42:287
  - BCR-ABL changes and expression, 42:9, 287
  - c-abl and c-sis in CML, 38:61
  - c-mos in t(8;16), 37:221
  - c-myc and n-myc in small cell lung cancer, 38:1
  - c-myc in lymphoma cell line, 40:73
  - CALLA gene on chromosome 3, 42:129
  - enzyme maps of 3p, 42:295
  - FGF-genes in tumors, 38:192
  - gli gene and fragment patterns, 41:237
  - in breast cancer, 41:219
  - in cancer family, 38:75
  - in CML, 42:9, 191
  - in familial breast-ovarian cancer, 38:241
  - in Hodgkin disease, 43:109
  - in human cancers, 38:161
  - in hydatidiform moles, 37:179
  - in leiomyomas with t(12;14), 39:195
  - in leukemia, 40:217; 42:9
  - in myelofibrosis, 38:101
  - in neuroblastoma, 41:153, 217, 218
  - in Ph negative, bcr+ CML, 43:51
  - in posttransplant CML using bcr, 43:67
  - in renal cancer in von Hippel-Lindau disease, 39:289
  - in retinoblastoma, 37:95, 133
  - in testicular tumors with i(12p), 40:129
  - in Wilms tumor, 38:121; 43:203
  - localization of cathepsin B gene on 13q14, 41:260
  - N-myc amplification in retinoblastoma, 37:133
  - of chromosome 6, 37:95
  - of dmin and HSR in retinoblastoma, 37:133
  - of hepatitis B viral DNA, 37:273
  - of heterochromatin in CML, 39:139
  - of rearranged Y in testicular tumor cell lines, 37:141
  - protooncogene studies in cancer family, 38:75
  - pulsed-field gel electrophoresis of BCR-ABL in CML, 42:287
  - refining cytogenetic data and, 41:244
  - restriction maps of 3p, 42:295
  - RFLP studies in testicular tumors, 40:129
  - TcR rearrangements in myeloid leukemic cells, 37:193
- Monocytes
  - del(3)(q21) in AMMoL, 37:29
- Monosomy
  - 5 and -7 in MDS and t-ANLL, 37:1; 42:43
  - 5 in secondary ANLL, 42:43
  - 7 in ANLL, 40:195; 41:12; 42:45
  - 7 in childhood ANLL, 40:13
  - 7 in secondary ANLL, 42:43
  - 11 in lymphoma, 37:90

- 13 in an angioleiomyoma, 37:61
- 14 in lymphoma, 37:90
- 17 in secondary ANLL, 42:43
- Mouse
  - B-cell lymphoma, 38:25
  - chromosome 6 and 7 trisomy in premalignant lesions, 41:235
  - Hertwig anemia and histiocytic sarcoma, 41:257
  - lymphoma, homing pattern, 38:33
  - neuroblastoma cell lines, 42:99
  - NOR activity in normal and malignant tissues, 37:55
  - raf-1 oncogene on chromosome 6, 40:89
  - silver-positive NOR, 37:55
- Multiple myeloma
  - cell type identification, 39:203
  - premature chromosome condensation, 39:203
- Myelodysplasia and Myelodysplastic syndromes (MDS)
  - chromosome changes in, 37:1; 42:55; 43:227
  - clinical-cytogenetic correlations 40:149; 42:55
  - idic(X)(q13) in, 42:173
  - in a dysmorphic child, 38:9
  - inv(3) in MDS and abnormal thrombopoiesis 39:167
  - RAEB-t, 42:55
  - secondary, 43:227
  - t(5;7)(q11.2;p11.2) in, 37:1
  - t(6;9)(p23;q34) in, 42:212
  - therapy related, 43:227
  - 1q+ and 3q+ in, 38:9
  - 5 and 7 and occupation, 38:261
  - +13 in a case of RAEB, 37:153
- Myelofibrosis
  - chromosome changes in, 38:101
  - i(17q) in, 43:195
  - idic(X)(q13) in, 38:101
  - molecular studies in, 38:101; 43:195
  - primary, 38:101
  - t(6;9)(p23;q34) in acute, 42:21
- Myeloid disorders; also see
  - Myelodysplastic syndromes (MDS) and Acute nonlymphocytic leukemia (ANLL)
  - chromosome changes in, 37:1
  - cytogenetic changes in myelofibrosis, 38:101
  - t(1;7)(p11;p11) in, 38:49
  - t(5;7) in MDS and therapy related ANLL (t-ANLL), 37:1
  - t(8;16) in t-ANLL, 37:127
- Myelomonocytic leukemia
  - karyotypic evolution in, 38:205
  - subacute in twins, 38:205
- Myeloproliferative disorders (MPD)
  - chromosome changes in myelofibrosis, 38:101
  - Ph-negative, molecular studies, 43:195
- Nasopharyngeal cancer
  - chromosome studies in, 38:191
- Near-haploidy
  - in blast crisis (megakaryoblastic) of Ph+ CML, 39:133
- Nephroblastoma
  - cystic partially differentiated, 41:79
  - hyperdiploidy (including +8) in, 41:79
- Neural tumors
  - cytogenetics of, 41:276, 278
  - pediatric, chromosomes in, 41:276
- Neurinoma
  - chromosomes in, 41:278
- Neuroblastoma
  - cell line, 38:164
  - cell lines in nude mice, 41:263
  - cytogenetics of, 41:153, 263, 267; 42:147
  - fragile site 1p13.1 in patients, 40:135
  - genetics of, 41:153
  - molecular biology of, 41:153, 267
  - murine, cell lines, 42:99
  - N-myc amplification in, 38:163, 164; 41:217, 218
  - N-myc and 1p-, 41:217
  - primary, chromosomes of, 42:147
  - review of, 41:153
  - 1p- in, 42:147
- Neuroectodermal tumors
  - chromosome 22 and, 38:169; 41:228
- Neuroendocrine tumors
  - Merkel cell carcinoma, 38:43; 41:265
  - t(10;17)(q23;q21) in Merkel tumor, 41:265
- Neuroepithelioma
  - peripheral with t(1;16)(q23;q24), 41:269
- Neurofibromatosis
  - acoustic, 39:137
  - chromosome 17, 41:223
  - cytogenetic and molecular studies in, 38:171
  - molecular studies in, 41:224
  - neurofibrosarcoma in, 41:273
  - no chromosome 22 changes in acoustic, 39:137
  - RFLP studies in, 41:223
- Neurogenic tumors
  - chromosome changes in, 37:109; 38:171
- Nevoid basal cell carcinoma (NBCC)
  - chromosome fragility in syndrome, 42:273
  - SCE in syndrome, 42:273



- Nucleolus Organizer Regions (NOR)  
 activity in normal and malignant murine tissues, 37:55  
 silver-positive NOR, 37:55
- Oncocytoma  
 cytogenetics in renal, 41:288; 43:15  
 renal, DNA alterations, 41:243  
 thyroid, DNA alterations, 41:243
- Oncogene(s)  
 antioncogene on 22q, 41:228  
 BCR-ABL expression, 42:9  
 c-mos translocation in t(8;16), 38:221  
 c-myc and dmin, 41:236  
 c-myc and n-myc in small cell lung cancer, 38:1  
 c-myc in PC-3 cells, 41:239  
 c-myc involvement in lymphoma cell line without 8q24 change, 40:73  
 c-raf1 on 3p, 42:295  
 changes in neuroblastoma, 41:153  
 HER-2/neu in breast cancer, 41:219  
 HPV viral integration and protooncogenes, 42:162  
 in CLL, 43:147  
 in leiomyomas with t(12;14), 39:195  
 int-1 in lipoma, 42:143  
 myc genes in transformed cells, 41:216  
 N-myc amplification in retinoblastoma, 37:133  
 N-myc and 1p- in neuroblastoma, 41:217  
 oncogene studies in Wilms tumor, 38:121  
 raf1 on chromosome 6 in mouse, 40:89
- Osteosarcoma  
 chromosome 13 in, 38:89  
 complex karyotypes in, 38:89  
 cytogenetic changes in, 38:159, 160; 42:27  
 DNA analysis, 42:27  
 pediatric osteosarcomas, 38:89  
 xenografted, 42:27
- Ovary  
 allele loss on 6q, 11p and 17p, 41:243  
 cancer cell line, 38:13, 181  
 cell lines, drug resistant, 39:35  
 chromosome changes and drug related effects, 39:35  
 chromosome 14 in ovarian cancer, 38:180  
 cytogenetic studies, 38:13, 180, 181, 182, 183; 41:289, 290, 291; 43:1  
 familial cancer, linkage studies, 38:241  
 i(5p) in ovarian tumors, 38:180  
 interphase cytogenetics in cancer cell lines, 38:181
- 3p deletions and RFLP studies, 38:182  
 3p, 6q, 8p and 10q in cancer, 43:1
- Pancreas  
 chromosome changes in adenocarcinoma, 37:209  
 cytogenetic findings in p
- Papilloma  
 basal cell of skin, 39:227  
 chromosomes in a nasal, 39:29  
 multiple changes in, 37:235  
 nasal, 39:29  
 of skin (basosquamous), 37:235  
 unrelated clones in a nasal, 39:29
- Pheochromocytoma  
 chromosome 22 in, 38:189  
 cytogenetics in, 38:189; 42:230  
 in von Hippel-Lindau disease, 42:230
- Philadelphia chromosome (Ph)  
 ABL-BCR in CML, 42:287  
 bcr analysis, 37:169; 38:61; 42:191  
 c-abl and c-sis in, 38:61  
 in thrombocytopenia (variant Ph), 39:77  
 masked in Ph-, bcr+ CML, 43:5  
 molecular studies of, 38:61; 42:191  
 pulsed-field gel electrophoresis of BCR-ABL, 42:287  
 t(2;9;13;22)(q33;q34;q32;q11), variant, 38:63  
 t(2;9;22)(q31;q34;q11) variant, 42:194  
 t(2;9;22)(q33;q34;q11) variant, 38:63  
 t(6;9;9;10;22)(q24;p13;q34;p15;q11) variant, 42:194  
 t(6;9;12;22)(p21;q34;q24;q11) variant, 38:115  
 t(6;9;22)(p23;q34;q11) variant, 38:63  
 t(7;9;22)(q11;q34;q11) variant, 42:194  
 t(7;9;22)(q35;q34;q11) variant, 42:194  
 t(8;9;22)(p21;q34;q11) variant, 38:63  
 t(9;11;22)(q34;q11;q11) Ph, 37:169  
 t(9;11;22)(q34;q13;q11) variant, 42:194  
 t(9;11;22)(q34;q23;q11) variant, 38:63  
 t(9;13;22)(q34;q21;q11) variant, 42:194  
 t(9;14;22)(q34;q11;q11) variant, 38:63  
 t(9;14;22)(q34;q32;q11) variant, 38:63  
 t(9;15;22)(q34;q22;q11) variant, 38:115  
 t(9;15;22)(q34;q24;q11) variant, 38:63  
 t(9;16;22)(q34;q24;q11) variant, 38:63  
 t(9;17;22)(q34;q13;q11) variant, 38:63  
 t(10;22)(q26;q11) Ph, 37:169  
 t(11;22)(p15;q11) Ph, 37:169  
 variant Ph translocations, 37:169; 38:61, 115; 42:191
- Pineoblastoma  
 11q- (interstitial) in, 39:125; 41:285
- Pleura  
 common changes in metastatic tumors, 39:129

- metastatic adenocarcinomas to, 39:219
- Polycythemia vera (PV)
  - chromosome changes in, 40:121
  - der(1)t(1;9) in, 40:121
  - in situ hybridization studies, 40:121
- Polymorphism
  - of chromosome 16 heterochromatin in CML, 39:139
- Polyps
  - chromosome breakage in cancer with APC, 42:263
  - colonic (adenomatosis), 37:285
- Porokeratosis of Mibelli
  - chromosome changes in, 43:89
  - chromosome 3 in, 43:89
  - fibroblasts, cytogenetic changes in, 43:89
- Preleukemia; also see Myelodysplasia
  - C-bands in, 41:71
  - clinical-cytogenetic correlations, 40:149; 42:1
  - single chromosome changes, 42:1
- Premature chromosome condensation (PCC)
  - cytogenetic analysis using PCC, 41:249
  - detection of aneuploidy in normal tissue adjacent to cases with PCC, 41:250
  - in multiple myeloma, 39:203
  - induction of, 41:248
- Prognosis
  - chromosome changes and, 37:9
- Prostate
  - BPH tissue, 37:241
  - cell cultures, 37:241
  - chromosome changes in tumors of, 37:108, 241; 38:180; 41:281
  - cytogenetics of cell lines, 37:241; 41:281
  - double minutes (dmin) in cancer, 39:191
  - HSR in cell lines, 37:241
  - leiomyosarcoma of, 43:39
- Radiotherapy
  - breakpoints on chromosomes, 41:61
  - cytogenetic effects, 41:61
- Rearrangements
  - in lymphoma, 37:85
  - induced by melphalan, 37:65
- Refractory anemia with excess of blasts (RAEB)
  - chromosome changes in, 42:55
  - clinical and cytogenetic findings, 42:55
  - t(1;7)(p11;p11) in, 38:49
  - +13 in a case, 37:153
- Renal tumors; see Kidney
- Retinoblastoma
  - c-int1 in, 38:163
  - cell line with dmin and HSR, 37:133
  - cell line with N-myc amplification at HSR, 37:133
  - cell lines, 37:95, 133
  - chromosome changes in, 37:95; 42:203; 43:73
  - high resolution with 1000 bands, 40:55
  - homozygosity of 13q, 43:73
  - i(6p) in, 37:95
  - linkage analysis in families with, 38:163
  - mechanism of i(6p) formation, 37:95
  - multifocal origin, 41:252; 42:203
  - Rb gene, 43:73
  - Rb gene and sarcoma, 41:224
  - synchronization of cultured cells, 40:55
- Rhabdoid tumor
  - cell line, 41:276
  - karyotypic changes in, 41:258
- Rhabdomyosarcoma
  - der(2) in, 38:168
  - embryonal, initial steps in etiology, 41:269
  - gli amplification in, 41:258
- Ring chromosome(s)
  - in bladder cancer, 42:136, 137
  - in MEN IIA S, 37:23
  - in osteosarcomas, 38:89
  - r(3), acute leukemia and abnormal thrombopoiesis, 39:167
  - r(3) in MDS, 39:175
  - r(11) in secondary ANLL, 42:45
- Salivary gland
  - adenocarcinoma with 6q-, 39:153
  - cytogenetics of, 41:231
  - del(6)(q22q24) in tumor, 39:153
  - molecular studies in, 41:231
  - tumors, 38:185
  - 6q- in adenocarcinoma, 39:153
- Sarcoma
  - angiosarcoma, 41:268
  - changes in a chondrosarcoma, 41:115
  - chromosome changes in, 37:109, 38:159
  - clear cell of kidney, 41:123
  - Ewing tumor, 37:79
  - fibrosarcoma, 37:139
  - fibrosarcoma, chromosomes, 37:139; 39:21
  - fibrosarcoma, congenital, 39:21
  - granulocytic with t(7;8)(q34;p11); 38:194
  - granulocytic with t(12;13)(q12;q12), 38:194
  - in Li-Fraumeni syndrome, 42:221
  - leiomyosarcoma, gastric, 37:215
  - osteosarcoma, cytogenetics and DNA, 42:27
  - osteosarcomas, 38:89
  - synovial, 38:160, 215
  - t(10;17)(q22;p13) in clear cell sarcoma of kidney, 41:123

- 1p- in epithelioid sarcoma, 41:267
- +8,+11,+17,+20 in infantile fibrosarcoma, 40:137
- Secondary leukemias (t-ANLL); also see Acute nonlymphocytic leukemia
- ANLL in solid tumor vs hematologic conditions, 42:43
- chromosome changes in 37:1; 43:227
- chromosomes 5 and 7 and occupation, 38:261
- melphalan induced chromosome changes and, 37:65
- possible secondary ANLL with t(10;17)(p13;q12), 39:45
- t-ANLL (M4) with t(8;16), 37:127
- t(5;7) in, 37:1
- Sister chromatid exchange (SCE)
- betel quid chewing and, 37:291
- in mutagen exposed Chinese hamster cells, 41:251
- in nevoid basal cell carcinoma syndrome, 42:273
- in patients with cervical cancer, 43:79
- in xeroderma pigmentosum heterozygotes, 43:219
- UV induced in fibroblasts of melanoma cases, 41:129
- Sixth International Workshop on Chromosomes in Leukemia (6IWCC); also see Workshops
- AML in relapse, 40:187
- chromosomes in ALL in relapse, 40:163
- chromosomes in MDS and preleukemia, 40:149
- general report, 40:141
- karyotype and its clinical significance in AML, 40:203
- molecular genetics in leukemia, 40:217
- six-year follow-up in ALL, 40:171
- Skin
- basal cell papilloma, 39:227
- basosquamous papilloma, cytogenetics, 37:235
- benign tumor (basosquamous papilloma), 37:235
- chromosome changes in skin tumors, 37:235; 39:69, 227; 41:292
- diverse chromosome changes in squamous cell carcinoma, 39:69
- keratoacanthoma, 39:227
- Merkel cell tumor, 41:265
- squamous cell carcinoma, 39:69; 41:292
- t(9;12) in Bowen disease, 43:249
- Small bowel
- leiomyosarcoma of, 43:39
- Soft tissue tumors
- angiosarcoma, 41:268
- c-myb in malignant histiocytoma, 41:240
- cytogenetics and nosology, 41:229
- rhabdoid tumor, 41:258
- rhabdomyosarcoma, 41:258
- 1p- in epithelioid sarcoma, 41:267
- Solid tumors; see Tumors
- chromosome in, 38:156; 39:69; 41:233, 292
- jumping end-to-end dicentrics, 40:95
- multiple clones in, 41:233
- of cheek in case with XP, 40:95
- of skin, cytogenetics, 39:69; 41:233
- Stomach
- adenocarcinoma metastatic to pleura, 39:219
- c-erb 2 in, 38:196
- cytogenetic studies in cancer of, 38:196
- leiomyosarcoma, 27:215
- Symposium; see Workshops
- Synovial sarcoma
- chromosome changes in, 38:160, 215; 41:270
- t(X;12;18)(p11.2;q13;q11.2) in, 41:270
- T-cell
- lymphoma, chromosome changes, 41:13
- T-cell receptor(s) (TcR)
- TcR  $\beta$  and  $\lambda$  chain gene rearrangements, 37:193
- TcR changes in myeloid leukemia cells, 37:193
- Tables
- changes in CLL and possible oncogenes involved, 43:145, 147
- changes in lipoma, 42:144
- chromosome changes in childhood ANLL, 40:13
- chromosome changes in leiomyosarcoma, 43:42, 46
- chromosome changes in pancreatic cancer, 37:212
- chromosome changes in solid tumors, 37:112; 38:148
- chromosome 17 in cancer of cervix, 37:230
- DNA amplification, 38:150
- error of centromere separation in human diseases, 43:173
- in benign tumors, 38:151
- inv(16) and +22 in M4, 43:124, 125
- lipomas with chromosome 13 changes, 39:286
- partial deletions and loss of heterozygosity, 38:149
- t(3;5) in leukemia and MDS, 37:165
- t(6;9) in leukemia, 39:82
- t(6;9) with basophilia, 42:217



- t(8;16)(p11;p13) and variants, 41:71  
Xq13 involvement, 42:175, 177, 183  
+4 in ANLL, 43:215  
17q and 10p in leukemia, 39:51  
+22 as solid change or with other changes, 43:126
- Techniques; see Methods
- Tenth Anniversary of CGC  
ALL of childhood, 40:13  
cell matrix receptors, 41:19  
centromere structure and function, 43:151  
chromosomes in ovarian cancer, 43:1  
chronic lymphocytic leukemia, 43:143  
cytogenetics of renal tumors, 43:15  
Editorial, 40:1  
immunophenotype of aneuploid cells, 41:1  
molecular biology and genetics of human neuroblastoma, 41:153  
single chromosome changes in preleukemia, 42:1  
solid tumor cytogenetics, 40:3  
variable expression of BCR-ABL, 42:9  
viral integration into human genome, 42:157  
X chromosome and hematologic disorders, 42:173
- Testes  
chromosome changes in tumors, 37:107; 38:176, 177, 179; 41:105  
heterozygosity retained in tumors with i(12p), 40:129  
i(12p) in gonadal tumors, 38:178; 40:129; 41:105  
i(12p) in one component of mixed tumor, 41:105  
loss of heterozygosity, 38:176; 40:129  
malignant mixed, 41:105  
rearranged Y in tumor cell lines, 37:141  
resistance to cis-platin and karyotypes, 41:255  
RFLP studies on i(12p), 40:129  
tumor cell lines, 37:141
- Tetraploidy  
in skin fibroblasts in patients with colonic diseases, 39:245
- Therapy related ANLL and MDS; see Secondary leukemia and Myelodysplasia
- Third International Workshop on Chromosomes in Solid Tumors (IWCST)  
abstracts, 41:215-294  
overview, 41:211  
preface, 41:209
- Thrombocythemia  
cytogenetic findings in, 43:57  
in transformation, 43:57  
Ph positive with t(9;15;22), 39:77
- Thymoma(s)  
chromosome changes in, 38:193; 41:93  
multiple clonal changes in, 41:93
- Thymus  
NOR in murine tumors, 37:55
- Thyroid  
adenomas, cytogenetics of, 39:65; 41:274  
carcinomas, 41:273  
cytogenetic studies in tumors, 38:190, 191; 39:65; 41:273  
t(7;10)(q35;q21) in papillary carcinoma, 41:139  
t(10;19)(q22;p13 or q13) in an adenoma, 39:65
- Trisomy  
in ANLL, 41:12  
+4 and dmin in AML (M2), 39:295  
+4 in ANLL, 43:211  
+4 in M1, 43:211  
+4 in M2, 41:205  
+4 in M4, 43:211  
+7 in normal kidney tissue of RCC, 37:289  
+7 in transitional cell carcinoma of kidney, 41:149  
+8 and others in neuroblastoma, 41:79  
+8 and squamous differentiation in endometrial cancer, 39:185  
(1;3;7)(q31;p13;p13) in retinoblastoma, 37:96  
(1;4)(p22;q21) in oligodendroglioma, 39:271  
(1;4)(p31;p13) in secondary ANLL, 43:236  
(1;4)(p32;q35) in lymphoma, 37:88  
(1;4)(q11;p11) in RAEB-t, 41:57  
(1;4)(q23;q25) in CML, 42:256  
(1;6)(p22;q21) in lymphoma, 37:89  
(1;6)(q21;p23) in squamous cell carcinoma of skin, 39:72  
(1;6)(q23;p21) in leiomyoma, 42:51  
(1;6)(q23;q23) in lymphoma, 37:89  
(1;6)(q24;q21) in lymphoma, 37:89  
(1;6;11)(q21;p23q25;p15) in squamous cell carcinoma of skin, 39:72  
(1;7)(p11;p11) in myeloid disorders, 38:49  
(1;7)(p11;p11) in pancytopenia, 42:91  
(1;7)(p11;p11) in RAEB-t, 42:57, 91  
(1;7)(p22;q32) in hematologic disorder, 42:176  
(1;7)(p36;p15) in lymphoma, 37:88  
(1;7)(q13;q11) in ovarian cancer cell line, 38:15  
(1;7)(q21;p22) in pancreatic cancer, 37:209

- (1;8)(cen;cen) in ALL, 40:166  
 (1;8)(p34;p23) in oligodendroglioma, 39:271  
 (1;8)(p36;p12) in lymphoma, 37:88  
 (1;8)(q24;q21) in secondary M6, 42:45  
 (1;9)(p32;q34) in Ph negative CML, 37:169  
 (1;9)(p36;p13) in lymphoma, 37:88  
 (1;9)(q11;q11) in polycythemia vera, 40:121  
 (1;9)(q11;q11) in secondary ANLL, 43:235  
 (1;9)(q11;q13) in polycythemia vera, 40:121  
 (1;10;11)(p32;q24;q23) in ANLL, 43:214  
 (1;11)(p13;q23) in CLL, 41:89  
 (1;11)(p13.2;q23.1) in CLL, 41:89  
 (1;11)(q12;q24) in secondary ANLL, 43:235  
 (1;11)(q21;q23) in M4, 37:269  
 (1;11)(q21;q23) in retinoblastoma, 42:203  
 (1;11)(q23;q25) in thymoma, 41:93  
 (1;12)(p12;q13) in skin papilloma, 37:235  
 (1;12)(q21;q24.3) in synovial sarcoma, 38:205  
 (1;13)(p32;q34) in lymphoma, 37:88  
 (1;13)(p36;q14) in ANLL, 40:193  
 (1;13;22)(q22;q12;p13) in adamantoma, 42:187  
 (1;14)(p36;q24) in lymphoma, 37:88, 90  
 (1;14)(q25;q32) in childhood ANLL, 40:22  
 (1;15)(p11;q12) in ANLL, 40:193  
 (1;15)(p32;q22) in lymphoma, 37:88  
 (1;15)(q34;q13) in childhood ANLL, 40:22  
 (1;16)(q23;q24) in Ewing sarcoma, 41:269  
 (1;17)(p11;q11) in Ph+ CML, 39:92  
 (1;17)(q12;p11) in retinoblastoma, 42:203  
 (1;18)(p22 or p31;q11-12) in neuroblastoma, 42:147  
 (1;19)(q21;p13) in ALL, 40:166  
 (1;19)(q23;p13) in ALL, 37:9  
 (1;21)(p32;q22) in leiomyosarcoma, 43:46  
 (2;3)(q2;p24 or p26) in CLL, 41:13  
 +8 in ANLL, 40:195; 41:12  
 +8 in CMMoL, 37:29  
 +8 in M5, 40:47  
 +8,+11,+17,+20 in infantile fibrosarcoma, 40:137  
 +8,+11,+20 in a congenital fibrosarcoma, 39:21  
 +8,+14,+21 in Ewing tumor, 37:81  
 +9 in lymphoma, 37:91  
 +12 in uterine leiomyoma, 37:50  
 +13 in MDS, 37:153  
 +14: a new entity in ANLL, 43:35  
 +20 in AMMoL (M4), 39:25  
 +21,+22 in childhood ANLL, 40:13  
 +22 in M4, 43:119
- Translocations**  
 in ANLL (Tables), 40:200, 201  
 in lymphoma, 37:85  
 in ovarian cancers, 43:1  
 (X;2)(q13;q15) in hematologic disorder, 42:175  
 (X;3)(q24;p12) in RCC, 43:21  
 (X;3;11)(q24p21;q22;p11) in choriocarcinoma cell line, 38:239  
 (X;4)(p22;q31) in hematologic disorder, 42:176  
 (X;6)(p11;p11) in osteosarcoma, 42:30  
 (X;7)(p15;q13) in CML, 38:63  
 (X;9)(p11.2;p22) in hematologic disorder, 42:176  
 (X;9;22)(p11;q34;q11) in hematologic disorder, 42:176  
 (X;10)(q21;q24) in ovarian cancer cell line, 38:15  
 (X;11)(p22;q31) in hematologic disorder, 42:176  
 (X;11)(q13;p15) in hematologic disorder, 42:175  
 (X;11)(q13;q23) in childhood ANLL, 40:19  
 (X;12)(p22.3;q15) in leiomyoma (uterine), 37:50  
 (X;12;16)(p11.2;q13;q11.2) in synovial sarcoma, 41:270  
 (X;13)(p22;q12) in hematologic disorder, 42:176  
 (X;13)(p22.3;q12) in hematologic disorder, 42:176  
 (X;14)(q22;q11) in hematologic disorder, 42:176  
 (X;15)(q1?3;q1?5) in hematologic disorder, 42:175  
 (X;18)(p11;q11) in a fibrosarcoma, 37:139  
 (X;18)(q11.2;q11.2) in synovial sarcoma, 38:205  
 (X;19)(q23;q13) in childhood ANLL, 40:22  
 (Y;1)(q12;p36) in lymphoma, 37:88  
 (Y;22)(p13;q11) in porokeratosis of Mibelli, 43:92  
 (1;1)(p36;q21) in glioma, 40:115  
 (1;1)(p36;q22) in lymphoma, 37:88  
 (1;1)(p36;q24) in choriocarcinoma cell line, 38:233  
 (1;1)(q21;q36) in lymphoma, 37:88

- (1;1)(q43;q13) in choriocarcinoma cell line, 38:235  
 (1;2)(p13;q11) in leiomyosarcoma, 43:46  
 (1;3) in lymphoma, 37:279  
 (1;3)(p31;p12) in nasal papilloma, 39:29  
 (1;3)(p36;p25) in lymphoma, 37:88  
 (1;3)(p36;q21) in secondary ANLL, 43:234  
 (1;3)(q11;p21) in mesothelioma, 42:121  
 (1;3)(q12;p13) in ALL, 40:166  
 (1;3)(q23;p21) in RCC, 43:21  
 (1;3)(q31;p13) in retinoblastoma, 37:96  
 (2;3)(q13;p13) in RCC, 43:22  
 (2;3)(q32;q21) in RCC, 43:21  
 (2;4)(q35;p13) in gastric leiomyosarcoma, 37:219  
 (2;5)(p23;q35) in lymphoma, 41:259  
 (2;5)(q31;q31) in skin papilloma, 37:235  
 (2;6)(p16;q21) in CLL, 41:89  
 (2;6)(p23;q25) in lymphoma, 37:89  
 (2;6;11)(q21;q27;p13) in basal cell papilloma, 39:227  
 (2;7;5)(q37;q11;q33) in keratoacanthoma, 39:227  
 (2;8) in case of AIDS and Burkitt leukemia, 38:131  
 (2;9)(p11;p21) in lymphoma, 37:91  
 (2;9;13;22)(q33;q34;q32;q11) Ph, 38:63  
 (2;9;22)(q31;q34;q11) Ph, 42:194  
 (2;9;22)(q33;q34;q11) Ph, 38:63  
 (2;11)(q13;q14) in t-ANLL, 37:4  
 (2;11)(q33;p15) in ANLL, 41:12  
 (2;11;19)(q22;p13;q13.3) in leiomyosarcoma, 43:46  
 (2;12)(p11;p13) in ALL, 40:166  
 (2;13)(p14;q33) in cartilage tumors, 38:83  
 (2;13)(q32;p12) in cartilage tumors, 38:83  
 (2;14)(q24;q32) in childhood ANLL, 40:18  
 (2;15)(p23;q26) in a fibrosarcoma, 37:139  
 (2;19)(q32;p13) in ANLL, 40:194  
 (2;22)(q21;q37) in family cancer, 38:223  
 (3;3)(q12;q29) in basal cell cancer, 42:309  
 (3;3)(q21;q26.2) in ANLL, 39:174, 175  
 (3;3)(q21;q29) in porokeratosis of Mibelli, 43:92  
 (3;4)(q29;q25) in ANLL, 40:195  
 (3;5) in leukemia and MDS (Table), 37:165  
 (3;5)(p11;p11) in hematologic disorder, 42:176  
 (3;5)(p13;q13) in RCC of von Hippel-Landau disease, 42:230  
 (3;5)(p13;q31) in RCC, 43:21  
 (3;5)(p14;q22) in RCC, 43:22  
 (3;5)(p21;q31) in Ph negative CML, 37:163  
 (3;5)(q21;q31) in ANLL, 40:195  
 (3;6)(p11;q24) in secondary ANLL, 43:236  
 (3;6)(p12-13;p12-21.1) in RCC, 43:21  
 (3;6)(q21;p23) in Barrett's esophagus, 42:283  
 (3;7)(q26;q21) in Ph+ CML, 39:93  
 (3;8)(p14;q22) in RCC in von Hippel-Lindau syndrome, 41:242  
 (3;8)(p14.2;q24.1) in hereditary RCC (molecular studies), 42:295  
 (3;8)(q26;q23) in secondary ANLL, 43:234  
 (3;8;17)(q27;q11;q12) in M5, 42:67  
 (3;9)(p21;q21) in secondary ANLL, 43:234  
 (3;12)(p26;q24) in choriocarcinoma cell line, 38:237  
 (3;12)(q12;q23) in mesothelioma, 42:121  
 (3;12)(q27;q14) in lipoma, 42:144  
 (3;13)(p12;p11) in ovarian cancer cell line, 38:15  
 (3;15)(p11;q12) in ovarian cancer cell line, 38:15  
 (3;15)(q11;q11) in secondary ANLL, 43:236  
 (3;15)(q21;q24) in CML, 42:257  
 (3;17)(p12;q11.2) in secondary M2, 42:45  
 (3;17)(p21;q21) in squamous cell carcinoma of skin, 39:72  
 (3;18)(p23;q21) in synovial sarcoma, 38:205  
 (3;19)(q26;q13) in ANLL, 41:12  
 (3;20)(p21;q11) in ANLL, 40:193  
 (3;20)(q11.2 or p13;q13.2) in RCC, 43:21  
 (3;20)(q12;p13) in skin papilloma, 37:235  
 (3;21)(p14;p11) in porokeratosis of Mibelli, 43:92  
 (3;21)(q26.2;q22) in CML, 39:143  
 (3;21)(q27;q21) in ANLL, 40:193  
 (3;22)(q21;q13) in ANLL, 40:195  
 (4;5)(p13;q14) in secondary ANLL, 43:236  
 (4;5)(q13;p15) in CML, 42:258  
 (4;6)(q21;q25) in ALL, 40:166  
 (4;6)(q31;p23) in lipoma, 37:283  
 (4;7)(q12;q34) in ANLL, 40:196  
 (4;10)(q31;q22) in ANLL, 40:194  
 (4;11)(q21;p15) in childhood ANLL, 40:19  
 (4;11)(q21;q23) in ALL, 40:163  
 (4;12)(q24;q14) in lipoma, 42:144  
 (4;13)(p14;q13) in a fibrosarcoma, 37:139  
 (4;15)(q24;q26) in secondary M2, 42:45



- (4;17)(q12;p11) in CLL, 41:13  
 (5;6)(p12;q15) in mesothelioma, 42:121  
 (5;7)(q11.2;p11.2) in MDS and t-ANLL, 37:1  
 (5;8)(q13;p23) in glioma, 39:262  
 (5;10)(p11;p15) in porokeratosis of Mibelli, 43:92  
 (5;10)(q11;q26) in choriocarcinoma cell line, 38:237  
 (5;12)(p13;p13) in CML, 42:257  
 (5;14)(p14;q21) in secondary M6, 42:45  
 (5;14)(q14;q22) in RCC, 43:21  
 (5;14)(q22;q34) in mammary epithelium cell line, 39:105  
 (5;16)(q33;q22) in M1, 43:139  
 (5;17)(q11;q11) in secondary M2, 42:45  
 (5;17)(q13.2;q11.1) in secondary M2, 42:45  
 (5;17)(q21;q22) in secondary M2, 42:45  
 (5;18)(q11.2;q11.2) in synovial sarcoma, 38:205  
 (6;7)(p11;q34) in hematologic disorder, 42:176  
 (6;8)(q11;q11) in RCC, 43:22  
 (6;9)(p21;q34) in retinoblastoma, 42:203  
 (6;9)(p23;q34) in ANLL cases of sarcoidosis, 38:297  
 (6;9)(p23;q34) in ANLL (loss of Y), 39:81  
 (6;9)(p23;q34) in leukemias and MDS, 42:209  
 (6;9;9;10;22)(q24;p13;q34;p15;q11) Ph, 42:194  
 (6;9;12;22)(p21;q34;q24;q11) Ph, 38:45  
 (6;9;22)(p23;q34;q11) Ph, 38:63  
 (6;10)(q21;q26) in a thyroid cancer, 41:273  
 (6;11)(p21.1;q13.1) in renal cancer, 43:21  
 (6;11)(p23;q13) in lipoma, 37:283  
 (6;11)(q25;p15) in squamous cell carcinoma of skin, 39:72  
 (6;12)(p23;p13) in mammary epithelium cell line, 39:105  
 (6;14)(q23;q22) in ANLL, 40:196  
 (6;14)(q23 or 25;q32) in childhood ANLL, 40:22  
 (6;16)(p11;q23-4) in glioma, 40:115  
 (6;16)(p22;q21) in secondary ANLL, 43:234  
 (6;17)(q11;q25) in mammary epithelium cell line, 39:105  
 (6;18)(q27;q12) in CML, 42:257  
 (6;21)(p21;q22) in childhood ANLL, 40:22  
 (6;22)(q27;q11) in secondary ANLL, 43:236  
 (7;9;22)(q11;q34;q11) Ph, 42:194  
 (7;9;22)(q35;q34;q11) Ph, 42:194  
 (7;10)(q11.2;q24) in glioma, 39:263  
 (7;10)(q35;q21) in papillary carcinoma of thyroid, 41:139  
 (7;12)(q35;q22) in childhood ANLL, 40:19  
 (7;14)(p11;p13) in squamous cell carcinoma of skin, 39:72  
 (7;14)(p15;q34) in childhood ANLL, 40:22  
 (7;15)(q11.2;q12) in glioma, 29:262  
 (7;15;16)(q11;q11;q11) in secondary ANLL, 43:236  
 (7;17)(p13;p13) in skin papilloma, 37:235  
 (7;17)(q11;q11) in RAEB-t, 42:57  
 (7;19)(q21;q13) in ANLL, 40:193  
 (7;22)(q11;q13) in a fibrosarcoma, 37:139  
 (8;9;22)(p21;q34;q11) Ph, 38:63  
 (8;11)(q11;p11) in medulloblastoma, 38:255  
 (8;12)(p11;p11) in t-ANLL, 37:4  
 (8;12)(q11.2;p11.2) in glioma, 39:262  
 (8;12)(q12;p12) in childhood ANLL, 40:22  
 (8;13)(q22;q12) in lipoma, 39:281  
 (8;14)(q24;q32) in ALL, 40:166  
 (8;14)(q24.1;q32.3) in lymphoma, 40:73  
 (8;15)(p21;q21) in skin papilloma, 37:235  
 (8;16)(p11;p13) in childhood ANLL, 40:22  
 (8;16)(p11;p13) in M4 following Hodgkin disease, 37:127  
 (8;16)(q22;q24) in AML and Down syndrome, 37:221  
 (8;17)(p11;p11) in t-ANLL, 37:4  
 (8;17)(p22;q21) in ANLL, 40:194  
 (8;18)(p21.2;q21.2) in secondary M5, 42:45  
 (8;21)(q22;q22) in childhood ANLL, 40:13  
 (8;21)(q22;q22) in M2, 40:105  
 (8;22)(q22;q11-12) in childhood ANLL, 40:22  
 (9;9)(p13;q24) in glioma, 40:115  
 (9;9)(p13;q34) in Ph negative, bcr+ CML, 43:51  
 (9;10)(p24?p12) in secondary ANLL, 43:236  
 (9;11)(p21;q23) in childhood ANLL, 40:13  
 (9;11)(p22;q13) in childhood ANLL, 40:22  
 (9;11)(q12;q13) in choriocarcinoma cell line, 38:235  
 (9;11)(q12;q25) in gastric leiomyosarcoma, 37:219

- (9;11)(q21;q24) in secondary M4, 42:45  
 (9;11)(q34;q12-13) in childhood ANLL, 40:22  
 (9;11;22)(q34;q13;q11), complex Ph, 37:169  
 (9;11;22)(q34;q13;q11) Ph, 42:194  
 (9;11;22)(q34;q23;q11) Ph, 38:63  
 (9;12)(p13;q24) in ALL, 37:293  
 (9;12)(q21;p11) in ANLL, 40:194  
 (9;12)(q32;q21) in Bowen disease, 43:249  
 (9;13;22)(q34;q21;q11) Ph, 42:194  
 (9;14;22)(q34;q11;q11) Ph, 38:63  
 (9;14;22)(q34;q32;q11) PH, 38:63  
 (9;15)(p11;q11) in glioma, 40:115  
 (9;15)(q12;q11.2) in glioma, 39:263  
 (9;15;22)(q34;q22;q11) Ph, 38:115  
 (9;15;22)(q34;q24;q11) Ph, 38:63  
 (9;15;22)(q34.1 or q34.3;q26.1;q11 or q13) Ph, 39:77  
 (9;16;22)(q34;q24;q11) Ph, 38:63  
 (9;17;22)(q34;p13;q11) Ph, 38:63  
 (9;19)(p13;q13) in glioma, 40:115  
 (9;21)(p11;p11) in glioma, 40:115  
 (9;22)(q34;q11) in ALL, 40:163  
 (9;22)(q34;q11) in CLL, 41:89  
 (9;22)(q34;q11) in CML (Ph+), 37:169  
 (9;22)(q34;q11) in RAEB-t, 42:57  
 (10;10)(p11;q26) in basal cell cancer, 42:309  
 (10;11)(p11;q23) in childhood ANLL, 40:19  
 (10;11)(p12;q14) in secondary M2, 42:45  
 (10;11)(p14;q21) in childhood ANLL, 40:22  
 (10;11)(p15;q21) in ANLL, 41:12  
 (10;11)(q?24;q?23) in ANLL, 40:194  
 (10;12)(p15;q13) in glioma, 39:262  
 (10;13)(p15;q22) in childhood ANLL, 40:22  
 (10;16)(q22;q13) in Ph+ CML, 39:92  
 (10;17)(p13;q12) in ANLL, 39:45  
 (10;17)(q22;p13) in clear cell sarcoma of kidney, 41:123  
 (10;17)(q22.1;p13) in leiomyosarcoma, 43:46  
 (10;17)(q23;q21) in Merkel cell tumor, 41:265  
 (10;19)(q22;p13 or q13) in thyroid adenoma, 39:65  
 (10;20;16)(q23;q11;p13) in childhood ANLL, 40:22  
 (10;22)(q26;q11), variant Ph, 37:169  
 (11;12)(q12;p11.2) in leiomyoma (uterine), 37:50  
 (11;12)(q13;q22) in lipoma, 37:283  
 (11;12)(q23;p13) in childhood ANLL, 40:19  
 (11;12)(q23;q13) in lipoma, 39:281  
 (11;14)(q13;p11) in breast cancer, 39:222  
 (11;14)(q23;q22) in CLL, 41:89  
 (11;14)(q23;q32) in ALL, 40:166  
 (11;14;17)(q13;q12;?) in CLL, 41:13  
 (11;17)(q13;q12) and t(7;12)(p15;p13) in APL, 43:103  
 (11;17)(q21;q11.2) in acute leukemia, 39:174  
 (11;17)(q23;q21) in childhood ANLL, 40:19  
 (11;19)(q12;p13) in leiomyosarcoma, 43:42  
 (11;19)(q13;p13) in secondary ANLL, 43:236  
 (11;21)(p12.2;p12) in secondary M2, 42:45  
 (11;22)(p15;q11), variant Ph, 37:169  
 (11;22)(q24;q21) in Ewing tumor, 37:79  
 (12;13)(p12.1;q13) in secondary M2, 42:45  
 (12;14)(q15;q24) in a uterine leiomyoma, 37:157  
 (12;16)(q13;q24) in childhood ANLL, 40:19  
 (12;16)(q22;q24) in CML (blast crisis) 39:174  
 (12;17)(p11.2;q11.2) in synovial sarcoma, 38:205  
 (12;17)(p13;q21) in ALL, 40:166  
 (12;18)(p12;q11) in secondary ANLL, 43:236  
 (12;19)(q13;p13) in glioma, 40:115  
 (12;21)(q11;q22) in secondary ANLL, 43:236  
 (13;13)(q11;q11) in glioma, 40:115  
 (13;13;13)(p12;q12q34;q12) in choriocarcinoma cell line, 38:239  
 (13;15)(p12;q12) in choriocarcinoma cell line, 38:235  
 (13;16)(q13-14;p11-12) in childhood ANLL, 40:22  
 (13;17)(q12-14;p12-13) in lymphoma, 43:243  
 (13;18)(q14;q23) in childhood ANLL, 40:19  
 (14;18)(q32;q21) in lymphoma, 41:13  
 (14;22)(q23;q13) in Ph+ CML, 39:92  
 (15;16)(?q21;p11) in stomach cancer, 39:223  
 (15;17)(q12;p13) in adamantinoma, 42:187  
 (15;17)(q22;q21) in ANLL, 40:197  
 (15;17)(q22;q21) in childhood ANLL, 40:13  
 (15;17)(q22;q25) in glioma, 40:115  
 (15;19)(q15;q13.4) in liver hamartoma, 40:29

- (15;22)(q21;q11) in mesothelioma, 42:121
- (16;21)(q24;q22) in childhood ANLL, 40:22
- (17;19)(p13;q13) in childhood ANLL, 40:18
- (17;19)(q11;q13) in ALL, 37:9
- (17;19)(q22;q13) in ANLL, 41:12
- (17;21)(q22;q21) in ANLL, 40:193
- (17;22)(q22;p11) in porokeratosis of Mibelli, 43:92
- (18;20)(q11.2;q13.3) in leiomyosarcoma, 43:42
- (20;21)(p11;p12) in choriocarcinoma cell line, 38:235
- (20;21)(p11;q11) in mesothelioma, 42:121
- Tumors**
  - angioleiomyoma, 37:61
  - benign, 37:110
  - bladder, 37:107
  - chromosome changes in solid tumors, 37:103; 38:147, 153, 154
  - chromosomes and clinical outcome, 41:234
  - chromosomes in pediatric, 38:165, 168
  - culture techniques, 41:262
  - cytogenetics and nosology, 41:229
  - cytogenetics of solid tumors, 40:3
  - digestive tract, 37:108
  - embryonal, 37:109
  - Ewing, 37:79
  - fibrosarcoma, 37:139
  - gastric leiomyosarcoma, 37:215
  - lung cancers, 37:108
  - melanomas, 37:108
  - Merkel cell, 38:43
  - neural (pediatric), 41:276
  - neurogenic, 37:109
  - of cartilage, 38:83
  - of cervix uteri, 37:229
  - of skin, 37:235
  - of uterus (leiomyoma), 37:49
  - overview on, 41:211
  - pancreatic cancer, 37:209
  - primary and secondary chromosome changes, 41:264
  - progression, 41:252
  - prostate, 37:108
  - recurrent karyotypic changes in solid tumors (Table), 37:112
  - renal, 37:108
  - retinoblastoma, 37:95
  - review of chromosome changes in, 37:103
  - sarcomas, 37:109
  - significance of chromosome changes, 37:103
  - suppression and monochromosome transfer, 41:234
  - technical aspects of chromosome analysis, 37:104
  - testicular, 37:107
  - Third International Workshop, 41:207
  - urogenital, 37:107
  - Workshop (European) on, 38:145
  - 11q13 in, 38:192
- Twins**
  - myelomonocytic leukemia and karyotypic evolution in, 38:205
- Urogenital tumors**
  - chromosome changes in, 37:107
- Uterus**
  - chromosome changes in, 37:49, 157; 38:181; 41:289, 290
  - chromosome 12 in, 37:49, 157
  - del(10)(q24) in cervical cancer, 41:232, 289
  - endometrial cancer, 41:290
  - inv(12)(p11.2q13) in endometrial polyp, 41:99
  - leiomyoma with t(12;14) and 7q-, 37:157
  - leiomyomas, 37:49, 157
  - leiomyosarcoma of, 43:39
  - +8 and squamous differentiation in endometrial cancer, 39:185
  - 17p- in cervical cancer, 37:229
- Virus(es)**
  - effects of SV40 in diploid fibroblasts, 41:235
  - hepatitis B in a transgenic mouse, 37:273
  - instability of hepatitis B virus, 37:273
  - papilloma (type 18) DNA in cervical cancer cell lines, 38:53
  - sites for viral integration in mammalian genome, 42:157
  - SV40 induced reversion to normal phenotype, 37:39
- von Hippel-Lindau disease**
  - cerebellar hemangioblastoma, 42:227
  - cytogenetics in tumors, 42:227
  - fragile site expression in families, 39:157
  - loss of heterozygosity on 3p in renal cancer, 39:289; 41:241
  - pheochromocytoma in, 38:189; 42:227
  - renal cell carcinoma in, 39:289; 41:242
  - retinal angioma, 42:227
  - 3p-, molecular studies in tumor, 41:241



- von Recklinghausen disease; see  
Neurofibromatosis
- Wilms tumor; also see Kidney  
adult type, 38:121; 42:35  
chromosome 1 in, 43:203  
cytogenetics of, 38:162; 41:222, 294;  
42:35; 43:203  
molecular studies, 38:121; 41:222;  
43:203  
RFLP analysis, 38:121  
11p13 in, 41:222
- Workshops and Symposia  
abstracts, 38:153-204; 39:1-19;  
40:141-203  
First European Workshop on  
Cytogenetics and Molecular Genetics  
of Human Solid Tumors, 38:145  
Frontiers in Cancer Research, 39:1-19  
Hayashibara Forum 1988, 39:1-19  
overview, 38:147  
Sixth International Workshop on  
Leukemia (see also Sixth  
International), 40:141-230
- X chromosome  
del(X) in ANLL, 40:22  
del(X) in hematologic disorders, 42:173  
del(X) in porokeratosis of Mibelli, 43:92  
der(X) in osteosarcoma, 42:30  
idic(X) in myelofibrosis, 38:101  
in primary myelofibrosis, 38:104  
isochromosome X in hematologic  
disorder, 42:176  
loss of X in gliomas, 39:253  
t(X;2)(q13;q15) in hematologic disorder,  
42:175  
t(X;3)(q24;p12) in renal cell cancer,  
43:21  
t(X;3;11)(q24p21;q22;p11) in  
choriocarcinoma cell line, 38:239  
t(X;4)(p22;q31) in hematologic disorder,  
42:176  
t(X;6)(p11;p11) in osteosarcoma, 42:30  
t(X;7)(p15;q13) in CML, 38:63  
t(X;9)(p11.2;p22) in hematologic  
disorder, 42:176  
t(X;9;22)(p11;q34;q11) in hematologic  
disorder, 42:176  
t(X;10)(q21;q24) in ovarian cancer cell  
line, 38:15  
t(X;11)(p22;q31) in hematologic  
disorder, 42:176  
t(X;11)(q13;p15) in hematologic  
disorder, 42:175  
t(X;11)(q13;q23) in childhood ANLL,  
40:19  
t(X;12)(p22.3;q15) in uterine leiomyoma,  
37:50  
t(X;12;16)(p11.2;q13;q11.2) in synovial  
sarcoma, 41:270  
t(X;13)(p22;q12) in hematologic  
disorder, 42:176  
t(X;13)(p22.3;q21) in hematologic  
disorder, 42:176  
t(X;14)(q22;q11) in hematologic  
disorder, 42:176  
t(X;15)(q1?3;q1?5) in hematologic  
disorder, 42:175  
t(X;18)(p11;q11) in a fibrosarcoma,  
37:139  
t(X;18)(q11.2;q11.2) in synovial sarcoma,  
38:205  
t(X;19)(q23;q13) in childhood ANLL,  
40:22 JAN  
translocations with X, 42:173  
X chromosome and hematologic  
disorders, 42:173  
-X in adult Wilms tumor, 42:35  
Xq13 involvement, 42:175
- Xeroderma pigmentosum  
case with squamous cell carcinoma of  
cheek, 40:95  
changes in fibroblasts, 43:219  
clonal rearrangements in, 38:157  
grouping end-to-end dicentrics, 40:95  
heterozygous carriers, 43:219  
hypodiploid karyotype in transformed  
cell cultures, 40:65  
SCE in heterozygotes, 43:219  
UV induced chromosome changes,  
43:219
- Y chromosome  
C-bands in leukemia and preleukemia,  
41:71  
in choriocarcinoma cell lines, 38:229  
loss of Y in ANLL, 39:81  
loss of Y in ANLL with t(6;9), 39:81  
loss of Y in Barrett's esophagus, 42:281  
loss of Y in CLL, 41:89  
loss of Y in gliomas, 39:253  
molecular studies in testicular tumor  
cell lines, 37:141  
rearranged Y in testicular tumor cell  
lines, 37:141  
t(Y;1)(q12;p36) in lymphoma, 37:88  
t(Y;22) in porokeratosis of Mibelli, 43:92



